Businessweek

Apptio%2C%20Inc.%20announced%20that%20it%20will%20raise%20%2445%2C000%2C011%20in%20funding%20on%20May%203%2C%202013.%20The%20company%20will%20issue%20common%20stock%20pursuant%20to%20exemption%20provided%20under%20Regulation%20D%20from%2023%20investors.%20Allen%20%26%20Company%20LLC%20acted%20as%20placement%20agent%20of%20the%20company.%20The%20company%20paid%20a%20sales%20commission%20of%20%24580%2C000%20million%20to%20Allen%20%26%20Company%20LLC.

Apptio%2C%20Inc.%20announced%20that%20it%20will%20raise%20%2445%2C000%2C011%20in%20funding%20on%20May%203%2C%202013.%20The%20company%20will%20issue%20common%20stock%20pursuant%20to%20exemption%20provided%20under%20Regulation%20D%20from%2023%20investors.%20Allen%20%26%20Company%20LLC%20acted%20as%20placement%20agent%20of%20the%20company.%20The%20company%20paid%20a%20sales%20commission%20of%20%24580%2C000%20million%20to%20Allen%20%26%20Company%20LLC.

Apptio%2C%20Inc.%20announced%20that%20it%20will%20raise%20%2445%2C000%2C011%20in%20funding%20on%20May%203%2C%202013.%20The%20company%20will%20issue%20common%20stock%20pursuant%20to%20exemption%20provided%20under%20Regulation%20D%20from%2023%20investors.%20Allen%20%26%20Company%20LLC%20acted%20as%20placement%20agent%20of%20the%20company.%20The%20company%20paid%20a%20sales%20commission%20of%20%24580%2C000%20million%20to%20Allen%20%26%20Company%20LLC.

Apptio%2C%20Inc.%20announced%20that%20it%20will%20raise%20%2445%2C000%2C011%20in%20funding%20on%20May%203%2C%202013.%20The%20company%20will%20issue%20common%20stock%20pursuant%20to%20exemption%20provided%20under%20Regulation%20D%20from%2023%20investors.%20Allen%20%26%20Company%20LLC%20acted%20as%20placement%20agent%20of%20the%20company.%20The%20company%20paid%20a%20sales%20commission%20of%20%24580%2C000%20million%20to%20Allen%20%26%20Company%20LLC.

Apptio%2C%20Inc.%20announced%20that%20it%20will%20raise%20%2445%2C000%2C011%20in%20funding%20on%20May%203%2C%202013.%20The%20company%20will%20issue%20common%20stock%20pursuant%20to%20exemption%20provided%20under%20Regulation%20D%20from%2023%20investors.%20Allen%20%26%20Company%20LLC%20acted%20as%20placement%20agent%20of%20the%20company.%20The%20company%20paid%20a%20sales%20commission%20of%20%24580%2C000%20million%20to%20Allen%20%26%20Company%20LLC.

Apptio%2C%20Inc.%20announced%20that%20it%20will%20raise%20%2445%2C000%2C011%20in%20funding%20on%20May%203%2C%202013.%20The%20company%20will%20issue%20common%20stock%20pursuant%20to%20exemption%20provided%20under%20Regulation%20D%20from%2023%20investors.%20Allen%20%26%20Company%20LLC%20acted%20as%20placement%20agent%20of%20the%20company.%20The%20company%20paid%20a%20sales%20commission%20of%20%24580%2C000%20million%20to%20Allen%20%26%20Company%20LLC.

OvaScience%2C%20Inc.%20%28OTCBB%3AOVSC%29%20announced%20a%20private%20placement%20of%203%2C888%2C880%20common%20shares%20at%20%249%20per%20share%20for%20gross%20proceeds%20of%20%2434%2C999%2C920%20on%20March%2012%2C%202013.%20The%20transaction%20will%20include%20participation%20from%20accredited%20investors%20including%20existing%20investors%20Blackwell%20Partners%2C%20LLC%2C%20Cycad%20Group%2C%20LLC%2C%20Hunt%20BioVentures%2C%20LP%2C%20Longwood%20Fund%2C%20LP%2C%20and%20RA%20Capital%20Healthcare%20Fund%2C%20LP%2C%20a%20fund%20managed%20by%20RA%20Capital%20Management%2C%20LLC%2C%20and%20new%20investors%20including%20Adage%20Capital%20Partners%2C%20L.P.%2C%20a%20fund%20managed%20by%20Adage%20Capital%20Management%2C%20L.P.%2C%20D3%20LifeScience%20Ltd.%2C%20Jenop%20Global%20Healthcare%20Fund%20Ltd%2C%20Franklin%20Templeton%20Investment%20Funds%20-%20Biotechnology%20Discovery%20Fund%2C%20Franklin%20Strategic%20Series%20-%20Franklin%20Biotechnology%20Discovery%20Fund%2C%20funds%20managed%20by%20Franklin%20Resources%20Inc.%2C%20Pacific%20Select%20Fund%20-%20Health%20Sciences%20Portfolio%2C%20a%20fund%20managed%20by%20Pacific%20Life%20Insurance%20Co.%2C%20Asset%20Management%20Arm%2C%20Kevin%20Beck%2C%20El%20Chichon%20Partners%2C%20LLC%2C%20BioBrit%2C%20LLC%2C%20BMV%20Direct%20LP%2C%20Jon-Erik%20Borgen%2C%20Borgen%20Equity%20III%20Holdings%2C%20LLC%2C%20Jeffrey%20David%20Capello%2C%20DAFNA%20Life%20Science%20Ltd%2C%20DAFNA%20Life%20Science%20Market%20Neutral%20Ltd%2C%20DAFNA%20Life%20Science%20Select%20Ltd%2C%20Deerfield%20Special%20Situations%20Fund%2C%20L.P.%2C%20Deerfield%20Special%20Situations%20International%20Master%20Fund%2C%20L.P.%2C%20funds%20managed%20by%20Deerfield%20Capital%2C%20L.P.%2C%20EcoR1%20Capital%20Fund%2C%20L.P.%2C%20EcoR1%20Capital%20Fund%2C%20L.P.%2C%20Hunt-BioVentures%2C%20L.P.%2C%20Janus%20Global%20Life%20Sciences%20Fund%2C%20a%20fund%20managed%20by%20INTECH%20Investment%20Management%20LLC%20and%20Janus%20Capital%20Group%2C%20Inc.%2C%20Jennison%20Global%20Healthcare%20Master%20Fund%2C%20Ltd.%2C%20a%20fund%20managed%20by%20Jennison%20Associates%20LLC%2C%20Edward%20F.%20Keely%2C%20Patrick%20Lin%2C%20Thomas%20Malley%2C%20Prudential%20Sector%20Funds%20Inc-Prudential%20Health%20Sciences%20Fund.%20The%20company%20has%20received%20%2448%2C000%2C000%20in%20funding%20till%20date.%20The%20transaction%20is%20expected%20to%20close%20by%20March%2018%2C%202013.%20Leerink%20Swann%20LLC%20will%20act%20as%20lead%20placement%20agent%20and%20Ladenburg%20Thalmann%20%26%20Co.%20Inc.%2C%20Oppenheimer%20%26%20Co.%20Inc.%2C%20Roth%20Capital%20Partners%2C%20LLC%20and%20Wedbush%20Securities%20Inc.%20will%20act%20as%20co-agents%20to%20the%20company%20in%20connection%20with%20the%20transaction.%20The%20company%20intends%20to%20pay%20the%20placement%20agents%20a%20fee%20which%20equals%20to%206%25%20of%20the%20gross%20proceeds%20of%20the%20transaction.%20The%20company%20expects%20to%20pay%20placement%20agent%20fees%20of%20approximately%20%241%2C600%2C000%20to%20Leerink%20Swann%20LLC%20and%20an%20aggregate%20of%20approximately%20%24500%2C000%20to%20Ladenburg%20Thalmann%20%26%20Co.%20Inc.%2C%20Oppenheimer%20%26%20Co.%20Inc.%2C%20Roth%20Capital%20Partners%2C%20LLC%2C%20and%20Wedbush%20Securities%20Inc.%20Lia%20Der%20Marderosian%20of%20Wilmer%20Cutler%20Pickering%20Hale%20and%20Dorr%2C%20LLP%20will%20act%20as%20the%20legal%20advisor%20to%20the%20company.%20The%20securities%20will%20be%20issued%20pursuant%20to%20exemption%20provided%20under%20Regulation%20D.

OvaScience%2C%20Inc.%20%28OTCBB%3AOVSC%29%20announced%20a%20private%20placement%20of%203%2C888%2C880%20common%20shares%20at%20%249%20per%20share%20for%20gross%20proceeds%20of%20%2434%2C999%2C920%20on%20March%2012%2C%202013.%20The%20transaction%20will%20include%20participation%20from%20accredited%20investors%20including%20existing%20investors%20Blackwell%20Partners%2C%20LLC%2C%20Cycad%20Group%2C%20LLC%2C%20Hunt%20BioVentures%2C%20LP%2C%20Longwood%20Fund%2C%20LP%2C%20and%20RA%20Capital%20Healthcare%20Fund%2C%20LP%2C%20a%20fund%20managed%20by%20RA%20Capital%20Management%2C%20LLC%2C%20and%20new%20investors%20including%20Adage%20Capital%20Partners%2C%20L.P.%2C%20a%20fund%20managed%20by%20Adage%20Capital%20Management%2C%20L.P.%2C%20D3%20LifeScience%20Ltd.%2C%20Jenop%20Global%20Healthcare%20Fund%20Ltd%2C%20Franklin%20Templeton%20Investment%20Funds%20-%20Biotechnology%20Discovery%20Fund%2C%20Franklin%20Strategic%20Series%20-%20Franklin%20Biotechnology%20Discovery%20Fund%2C%20funds%20managed%20by%20Franklin%20Resources%20Inc.%2C%20Pacific%20Select%20Fund%20-%20Health%20Sciences%20Portfolio%2C%20a%20fund%20managed%20by%20Pacific%20Life%20Insurance%20Co.%2C%20Asset%20Management%20Arm%2C%20Kevin%20Beck%2C%20El%20Chichon%20Partners%2C%20LLC%2C%20BioBrit%2C%20LLC%2C%20BMV%20Direct%20LP%2C%20Jon-Erik%20Borgen%2C%20Borgen%20Equity%20III%20Holdings%2C%20LLC%2C%20Jeffrey%20David%20Capello%2C%20DAFNA%20Life%20Science%20Ltd%2C%20DAFNA%20Life%20Science%20Market%20Neutral%20Ltd%2C%20DAFNA%20Life%20Science%20Select%20Ltd%2C%20Deerfield%20Special%20Situations%20Fund%2C%20L.P.%2C%20Deerfield%20Special%20Situations%20International%20Master%20Fund%2C%20L.P.%2C%20funds%20managed%20by%20Deerfield%20Capital%2C%20L.P.%2C%20EcoR1%20Capital%20Fund%2C%20L.P.%2C%20EcoR1%20Capital%20Fund%2C%20L.P.%2C%20Hunt-BioVentures%2C%20L.P.%2C%20Janus%20Global%20Life%20Sciences%20Fund%2C%20a%20fund%20managed%20by%20INTECH%20Investment%20Management%20LLC%20and%20Janus%20Capital%20Group%2C%20Inc.%2C%20Jennison%20Global%20Healthcare%20Master%20Fund%2C%20Ltd.%2C%20a%20fund%20managed%20by%20Jennison%20Associates%20LLC%2C%20Edward%20F.%20Keely%2C%20Patrick%20Lin%2C%20Thomas%20Malley%2C%20Prudential%20Sector%20Funds%20Inc-Prudential%20Health%20Sciences%20Fund.%20The%20company%20has%20received%20%2448%2C000%2C000%20in%20funding%20till%20date.%20The%20transaction%20is%20expected%20to%20close%20by%20March%2018%2C%202013.%20Leerink%20Swann%20LLC%20will%20act%20as%20lead%20placement%20agent%20and%20Ladenburg%20Thalmann%20%26%20Co.%20Inc.%2C%20Oppenheimer%20%26%20Co.%20Inc.%2C%20Roth%20Capital%20Partners%2C%20LLC%20and%20Wedbush%20Securities%20Inc.%20will%20act%20as%20co-agents%20to%20the%20company%20in%20connection%20with%20the%20transaction.%20The%20company%20intends%20to%20pay%20the%20placement%20agents%20a%20fee%20which%20equals%20to%206%25%20of%20the%20gross%20proceeds%20of%20the%20transaction.%20The%20company%20expects%20to%20pay%20placement%20agent%20fees%20of%20approximately%20%241%2C600%2C000%20to%20Leerink%20Swann%20LLC%20and%20an%20aggregate%20of%20approximately%20%24500%2C000%20to%20Ladenburg%20Thalmann%20%26%20Co.%20Inc.%2C%20Oppenheimer%20%26%20Co.%20Inc.%2C%20Roth%20Capital%20Partners%2C%20LLC%2C%20and%20Wedbush%20Securities%20Inc.%20Lia%20Der%20Marderosian%20of%20Wilmer%20Cutler%20Pickering%20Hale%20and%20Dorr%2C%20LLP%20will%20act%20as%20the%20legal%20advisor%20to%20the%20company.%20The%20securities%20will%20be%20issued%20pursuant%20to%20exemption%20provided%20under%20Regulation%20D.

OvaScience%2C%20Inc.%20%28OTCBB%3AOVSC%29%20announced%20a%20private%20placement%20of%203%2C888%2C880%20common%20shares%20at%20%249%20per%20share%20for%20gross%20proceeds%20of%20%2434%2C999%2C920%20on%20March%2012%2C%202013.%20The%20transaction%20will%20include%20participation%20from%20accredited%20investors%20including%20existing%20investors%20Blackwell%20Partners%2C%20LLC%2C%20Cycad%20Group%2C%20LLC%2C%20Hunt%20BioVentures%2C%20LP%2C%20Longwood%20Fund%2C%20LP%2C%20and%20RA%20Capital%20Healthcare%20Fund%2C%20LP%2C%20a%20fund%20managed%20by%20RA%20Capital%20Management%2C%20LLC%2C%20and%20new%20investors%20including%20Adage%20Capital%20Partners%2C%20L.P.%2C%20a%20fund%20managed%20by%20Adage%20Capital%20Management%2C%20L.P.%2C%20D3%20LifeScience%20Ltd.%2C%20Jenop%20Global%20Healthcare%20Fund%20Ltd%2C%20Franklin%20Templeton%20Investment%20Funds%20-%20Biotechnology%20Discovery%20Fund%2C%20Franklin%20Strategic%20Series%20-%20Franklin%20Biotechnology%20Discovery%20Fund%2C%20funds%20managed%20by%20Franklin%20Resources%20Inc.%2C%20Pacific%20Select%20Fund%20-%20Health%20Sciences%20Portfolio%2C%20a%20fund%20managed%20by%20Pacific%20Life%20Insurance%20Co.%2C%20Asset%20Management%20Arm%2C%20Kevin%20Beck%2C%20El%20Chichon%20Partners%2C%20LLC%2C%20BioBrit%2C%20LLC%2C%20BMV%20Direct%20LP%2C%20Jon-Erik%20Borgen%2C%20Borgen%20Equity%20III%20Holdings%2C%20LLC%2C%20Jeffrey%20David%20Capello%2C%20DAFNA%20Life%20Science%20Ltd%2C%20DAFNA%20Life%20Science%20Market%20Neutral%20Ltd%2C%20DAFNA%20Life%20Science%20Select%20Ltd%2C%20Deerfield%20Special%20Situations%20Fund%2C%20L.P.%2C%20Deerfield%20Special%20Situations%20International%20Master%20Fund%2C%20L.P.%2C%20funds%20managed%20by%20Deerfield%20Capital%2C%20L.P.%2C%20EcoR1%20Capital%20Fund%2C%20L.P.%2C%20EcoR1%20Capital%20Fund%2C%20L.P.%2C%20Hunt-BioVentures%2C%20L.P.%2C%20Janus%20Global%20Life%20Sciences%20Fund%2C%20a%20fund%20managed%20by%20INTECH%20Investment%20Management%20LLC%20and%20Janus%20Capital%20Group%2C%20Inc.%2C%20Jennison%20Global%20Healthcare%20Master%20Fund%2C%20Ltd.%2C%20a%20fund%20managed%20by%20Jennison%20Associates%20LLC%2C%20Edward%20F.%20Keely%2C%20Patrick%20Lin%2C%20Thomas%20Malley%2C%20Prudential%20Sector%20Funds%20Inc-Prudential%20Health%20Sciences%20Fund.%20The%20company%20has%20received%20%2448%2C000%2C000%20in%20funding%20till%20date.%20The%20transaction%20is%20expected%20to%20close%20by%20March%2018%2C%202013.%20Leerink%20Swann%20LLC%20will%20act%20as%20lead%20placement%20agent%20and%20Ladenburg%20Thalmann%20%26%20Co.%20Inc.%2C%20Oppenheimer%20%26%20Co.%20Inc.%2C%20Roth%20Capital%20Partners%2C%20LLC%20and%20Wedbush%20Securities%20Inc.%20will%20act%20as%20co-agents%20to%20the%20company%20in%20connection%20with%20the%20transaction.%20The%20company%20intends%20to%20pay%20the%20placement%20agents%20a%20fee%20which%20equals%20to%206%25%20of%20the%20gross%20proceeds%20of%20the%20transaction.%20The%20company%20expects%20to%20pay%20placement%20agent%20fees%20of%20approximately%20%241%2C600%2C000%20to%20Leerink%20Swann%20LLC%20and%20an%20aggregate%20of%20approximately%20%24500%2C000%20to%20Ladenburg%20Thalmann%20%26%20Co.%20Inc.%2C%20Oppenheimer%20%26%20Co.%20Inc.%2C%20Roth%20Capital%20Partners%2C%20LLC%2C%20and%20Wedbush%20Securities%20Inc.%20Lia%20Der%20Marderosian%20of%20Wilmer%20Cutler%20Pickering%20Hale%20and%20Dorr%2C%20LLP%20will%20act%20as%20the%20legal%20advisor%20to%20the%20company.%20The%20securities%20will%20be%20issued%20pursuant%20to%20exemption%20provided%20under%20Regulation%20D.

OvaScience%2C%20Inc.%20%28OTCBB%3AOVSC%29%20announced%20a%20private%20placement%20of%203%2C888%2C880%20common%20shares%20at%20%249%20per%20share%20for%20gross%20proceeds%20of%20%2434%2C999%2C920%20on%20March%2012%2C%202013.%20The%20transaction%20will%20include%20participation%20from%20accredited%20investors%20including%20existing%20investors%20Blackwell%20Partners%2C%20LLC%2C%20Cycad%20Group%2C%20LLC%2C%20Hunt%20BioVentures%2C%20LP%2C%20Longwood%20Fund%2C%20LP%2C%20and%20RA%20Capital%20Healthcare%20Fund%2C%20LP%2C%20a%20fund%20managed%20by%20RA%20Capital%20Management%2C%20LLC%2C%20and%20new%20investors%20including%20Adage%20Capital%20Partners%2C%20L.P.%2C%20a%20fund%20managed%20by%20Adage%20Capital%20Management%2C%20L.P.%2C%20D3%20LifeScience%20Ltd.%2C%20Jenop%20Global%20Healthcare%20Fund%20Ltd%2C%20Franklin%20Templeton%20Investment%20Funds%20-%20Biotechnology%20Discovery%20Fund%2C%20Franklin%20Strategic%20Series%20-%20Franklin%20Biotechnology%20Discovery%20Fund%2C%20funds%20managed%20by%20Franklin%20Resources%20Inc.%2C%20Pacific%20Select%20Fund%20-%20Health%20Sciences%20Portfolio%2C%20a%20fund%20managed%20by%20Pacific%20Life%20Insurance%20Co.%2C%20Asset%20Management%20Arm%2C%20Kevin%20Beck%2C%20El%20Chichon%20Partners%2C%20LLC%2C%20BioBrit%2C%20LLC%2C%20BMV%20Direct%20LP%2C%20Jon-Erik%20Borgen%2C%20Borgen%20Equity%20III%20Holdings%2C%20LLC%2C%20Jeffrey%20David%20Capello%2C%20DAFNA%20Life%20Science%20Ltd%2C%20DAFNA%20Life%20Science%20Market%20Neutral%20Ltd%2C%20DAFNA%20Life%20Science%20Select%20Ltd%2C%20Deerfield%20Special%20Situations%20Fund%2C%20L.P.%2C%20Deerfield%20Special%20Situations%20International%20Master%20Fund%2C%20L.P.%2C%20funds%20managed%20by%20Deerfield%20Capital%2C%20L.P.%2C%20EcoR1%20Capital%20Fund%2C%20L.P.%2C%20EcoR1%20Capital%20Fund%2C%20L.P.%2C%20Hunt-BioVentures%2C%20L.P.%2C%20Janus%20Global%20Life%20Sciences%20Fund%2C%20a%20fund%20managed%20by%20INTECH%20Investment%20Management%20LLC%20and%20Janus%20Capital%20Group%2C%20Inc.%2C%20Jennison%20Global%20Healthcare%20Master%20Fund%2C%20Ltd.%2C%20a%20fund%20managed%20by%20Jennison%20Associates%20LLC%2C%20Edward%20F.%20Keely%2C%20Patrick%20Lin%2C%20Thomas%20Malley%2C%20Prudential%20Sector%20Funds%20Inc-Prudential%20Health%20Sciences%20Fund.%20The%20company%20has%20received%20%2448%2C000%2C000%20in%20funding%20till%20date.%20The%20transaction%20is%20expected%20to%20close%20by%20March%2018%2C%202013.%20Leerink%20Swann%20LLC%20will%20act%20as%20lead%20placement%20agent%20and%20Ladenburg%20Thalmann%20%26%20Co.%20Inc.%2C%20Oppenheimer%20%26%20Co.%20Inc.%2C%20Roth%20Capital%20Partners%2C%20LLC%20and%20Wedbush%20Securities%20Inc.%20will%20act%20as%20co-agents%20to%20the%20company%20in%20connection%20with%20the%20transaction.%20The%20company%20intends%20to%20pay%20the%20placement%20agents%20a%20fee%20which%20equals%20to%206%25%20of%20the%20gross%20proceeds%20of%20the%20transaction.%20The%20company%20expects%20to%20pay%20placement%20agent%20fees%20of%20approximately%20%241%2C600%2C000%20to%20Leerink%20Swann%20LLC%20and%20an%20aggregate%20of%20approximately%20%24500%2C000%20to%20Ladenburg%20Thalmann%20%26%20Co.%20Inc.%2C%20Oppenheimer%20%26%20Co.%20Inc.%2C%20Roth%20Capital%20Partners%2C%20LLC%2C%20and%20Wedbush%20Securities%20Inc.%20Lia%20Der%20Marderosian%20of%20Wilmer%20Cutler%20Pickering%20Hale%20and%20Dorr%2C%20LLP%20will%20act%20as%20the%20legal%20advisor%20to%20the%20company.%20The%20securities%20will%20be%20issued%20pursuant%20to%20exemption%20provided%20under%20Regulation%20D.

OvaScience%2C%20Inc.%20%28OTCBB%3AOVSC%29%20announced%20a%20private%20placement%20of%203%2C888%2C880%20common%20shares%20at%20%249%20per%20share%20for%20gross%20proceeds%20of%20%2434%2C999%2C920%20on%20March%2012%2C%202013.%20The%20transaction%20will%20include%20participation%20from%20accredited%20investors%20including%20existing%20investors%20Blackwell%20Partners%2C%20LLC%2C%20Cycad%20Group%2C%20LLC%2C%20Hunt%20BioVentures%2C%20LP%2C%20Longwood%20Fund%2C%20LP%2C%20and%20RA%20Capital%20Healthcare%20Fund%2C%20LP%2C%20a%20fund%20managed%20by%20RA%20Capital%20Management%2C%20LLC%2C%20and%20new%20investors%20including%20Adage%20Capital%20Partners%2C%20L.P.%2C%20a%20fund%20managed%20by%20Adage%20Capital%20Management%2C%20L.P.%2C%20D3%20LifeScience%20Ltd.%2C%20Jenop%20Global%20Healthcare%20Fund%20Ltd%2C%20Franklin%20Templeton%20Investment%20Funds%20-%20Biotechnology%20Discovery%20Fund%2C%20Franklin%20Strategic%20Series%20-%20Franklin%20Biotechnology%20Discovery%20Fund%2C%20funds%20managed%20by%20Franklin%20Resources%20Inc.%2C%20Pacific%20Select%20Fund%20-%20Health%20Sciences%20Portfolio%2C%20a%20fund%20managed%20by%20Pacific%20Life%20Insurance%20Co.%2C%20Asset%20Management%20Arm%2C%20Kevin%20Beck%2C%20El%20Chichon%20Partners%2C%20LLC%2C%20BioBrit%2C%20LLC%2C%20BMV%20Direct%20LP%2C%20Jon-Erik%20Borgen%2C%20Borgen%20Equity%20III%20Holdings%2C%20LLC%2C%20Jeffrey%20David%20Capello%2C%20DAFNA%20Life%20Science%20Ltd%2C%20DAFNA%20Life%20Science%20Market%20Neutral%20Ltd%2C%20DAFNA%20Life%20Science%20Select%20Ltd%2C%20Deerfield%20Special%20Situations%20Fund%2C%20L.P.%2C%20Deerfield%20Special%20Situations%20International%20Master%20Fund%2C%20L.P.%2C%20funds%20managed%20by%20Deerfield%20Capital%2C%20L.P.%2C%20EcoR1%20Capital%20Fund%2C%20L.P.%2C%20EcoR1%20Capital%20Fund%2C%20L.P.%2C%20Hunt-BioVentures%2C%20L.P.%2C%20Janus%20Global%20Life%20Sciences%20Fund%2C%20a%20fund%20managed%20by%20INTECH%20Investment%20Management%20LLC%20and%20Janus%20Capital%20Group%2C%20Inc.%2C%20Jennison%20Global%20Healthcare%20Master%20Fund%2C%20Ltd.%2C%20a%20fund%20managed%20by%20Jennison%20Associates%20LLC%2C%20Edward%20F.%20Keely%2C%20Patrick%20Lin%2C%20Thomas%20Malley%2C%20Prudential%20Sector%20Funds%20Inc-Prudential%20Health%20Sciences%20Fund.%20The%20company%20has%20received%20%2448%2C000%2C000%20in%20funding%20till%20date.%20The%20transaction%20is%20expected%20to%20close%20by%20March%2018%2C%202013.%20Leerink%20Swann%20LLC%20will%20act%20as%20lead%20placement%20agent%20and%20Ladenburg%20Thalmann%20%26%20Co.%20Inc.%2C%20Oppenheimer%20%26%20Co.%20Inc.%2C%20Roth%20Capital%20Partners%2C%20LLC%20and%20Wedbush%20Securities%20Inc.%20will%20act%20as%20co-agents%20to%20the%20company%20in%20connection%20with%20the%20transaction.%20The%20company%20intends%20to%20pay%20the%20placement%20agents%20a%20fee%20which%20equals%20to%206%25%20of%20the%20gross%20proceeds%20of%20the%20transaction.%20The%20company%20expects%20to%20pay%20placement%20agent%20fees%20of%20approximately%20%241%2C600%2C000%20to%20Leerink%20Swann%20LLC%20and%20an%20aggregate%20of%20approximately%20%24500%2C000%20to%20Ladenburg%20Thalmann%20%26%20Co.%20Inc.%2C%20Oppenheimer%20%26%20Co.%20Inc.%2C%20Roth%20Capital%20Partners%2C%20LLC%2C%20and%20Wedbush%20Securities%20Inc.%20Lia%20Der%20Marderosian%20of%20Wilmer%20Cutler%20Pickering%20Hale%20and%20Dorr%2C%20LLP%20will%20act%20as%20the%20legal%20advisor%20to%20the%20company.%20The%20securities%20will%20be%20issued%20pursuant%20to%20exemption%20provided%20under%20Regulation%20D.

OvaScience%2C%20Inc.%20%28OTCBB%3AOVSC%29%20announced%20a%20private%20placement%20of%203%2C888%2C880%20common%20shares%20at%20%249%20per%20share%20for%20gross%20proceeds%20of%20%2434%2C999%2C920%20on%20March%2012%2C%202013.%20The%20transaction%20will%20include%20participation%20from%20accredited%20investors%20including%20existing%20investors%20Blackwell%20Partners%2C%20LLC%2C%20Cycad%20Group%2C%20LLC%2C%20Hunt%20BioVentures%2C%20LP%2C%20Longwood%20Fund%2C%20LP%2C%20and%20RA%20Capital%20Healthcare%20Fund%2C%20LP%2C%20a%20fund%20managed%20by%20RA%20Capital%20Management%2C%20LLC%2C%20and%20new%20investors%20including%20Adage%20Capital%20Partners%2C%20L.P.%2C%20a%20fund%20managed%20by%20Adage%20Capital%20Management%2C%20L.P.%2C%20D3%20LifeScience%20Ltd.%2C%20Jenop%20Global%20Healthcare%20Fund%20Ltd%2C%20Franklin%20Templeton%20Investment%20Funds%20-%20Biotechnology%20Discovery%20Fund%2C%20Franklin%20Strategic%20Series%20-%20Franklin%20Biotechnology%20Discovery%20Fund%2C%20funds%20managed%20by%20Franklin%20Resources%20Inc.%2C%20Pacific%20Select%20Fund%20-%20Health%20Sciences%20Portfolio%2C%20a%20fund%20managed%20by%20Pacific%20Life%20Insurance%20Co.%2C%20Asset%20Management%20Arm%2C%20Kevin%20Beck%2C%20El%20Chichon%20Partners%2C%20LLC%2C%20BioBrit%2C%20LLC%2C%20BMV%20Direct%20LP%2C%20Jon-Erik%20Borgen%2C%20Borgen%20Equity%20III%20Holdings%2C%20LLC%2C%20Jeffrey%20David%20Capello%2C%20DAFNA%20Life%20Science%20Ltd%2C%20DAFNA%20Life%20Science%20Market%20Neutral%20Ltd%2C%20DAFNA%20Life%20Science%20Select%20Ltd%2C%20Deerfield%20Special%20Situations%20Fund%2C%20L.P.%2C%20Deerfield%20Special%20Situations%20International%20Master%20Fund%2C%20L.P.%2C%20funds%20managed%20by%20Deerfield%20Capital%2C%20L.P.%2C%20EcoR1%20Capital%20Fund%2C%20L.P.%2C%20EcoR1%20Capital%20Fund%2C%20L.P.%2C%20Hunt-BioVentures%2C%20L.P.%2C%20Janus%20Global%20Life%20Sciences%20Fund%2C%20a%20fund%20managed%20by%20INTECH%20Investment%20Management%20LLC%20and%20Janus%20Capital%20Group%2C%20Inc.%2C%20Jennison%20Global%20Healthcare%20Master%20Fund%2C%20Ltd.%2C%20a%20fund%20managed%20by%20Jennison%20Associates%20LLC%2C%20Edward%20F.%20Keely%2C%20Patrick%20Lin%2C%20Thomas%20Malley%2C%20Prudential%20Sector%20Funds%20Inc-Prudential%20Health%20Sciences%20Fund.%20The%20company%20has%20received%20%2448%2C000%2C000%20in%20funding%20till%20date.%20The%20transaction%20is%20expected%20to%20close%20by%20March%2018%2C%202013.%20Leerink%20Swann%20LLC%20will%20act%20as%20lead%20placement%20agent%20and%20Ladenburg%20Thalmann%20%26%20Co.%20Inc.%2C%20Oppenheimer%20%26%20Co.%20Inc.%2C%20Roth%20Capital%20Partners%2C%20LLC%20and%20Wedbush%20Securities%20Inc.%20will%20act%20as%20co-agents%20to%20the%20company%20in%20connection%20with%20the%20transaction.%20The%20company%20intends%20to%20pay%20the%20placement%20agents%20a%20fee%20which%20equals%20to%206%25%20of%20the%20gross%20proceeds%20of%20the%20transaction.%20The%20company%20expects%20to%20pay%20placement%20agent%20fees%20of%20approximately%20%241%2C600%2C000%20to%20Leerink%20Swann%20LLC%20and%20an%20aggregate%20of%20approximately%20%24500%2C000%20to%20Ladenburg%20Thalmann%20%26%20Co.%20Inc.%2C%20Oppenheimer%20%26%20Co.%20Inc.%2C%20Roth%20Capital%20Partners%2C%20LLC%2C%20and%20Wedbush%20Securities%20Inc.%20Lia%20Der%20Marderosian%20of%20Wilmer%20Cutler%20Pickering%20Hale%20and%20Dorr%2C%20LLP%20will%20act%20as%20the%20legal%20advisor%20to%20the%20company.%20The%20securities%20will%20be%20issued%20pursuant%20to%20exemption%20provided%20under%20Regulation%20D.

OvaScience%2C%20Inc.%20%28OTCBB%3AOVSC%29%20announced%20a%20private%20placement%20of%203%2C888%2C880%20common%20shares%20at%20%249%20per%20share%20for%20gross%20proceeds%20of%20%2434%2C999%2C920%20on%20March%2012%2C%202013.%20The%20transaction%20will%20include%20participation%20from%20accredited%20investors%20including%20existing%20investors%20Blackwell%20Partners%2C%20LLC%2C%20Cycad%20Group%2C%20LLC%2C%20Hunt%20BioVentures%2C%20LP%2C%20Longwood%20Fund%2C%20LP%2C%20and%20RA%20Capital%20Healthcare%20Fund%2C%20LP%2C%20a%20fund%20managed%20by%20RA%20Capital%20Management%2C%20LLC%2C%20and%20new%20investors%20including%20Adage%20Capital%20Partners%2C%20L.P.%2C%20a%20fund%20managed%20by%20Adage%20Capital%20Management%2C%20L.P.%2C%20D3%20LifeScience%20Ltd.%2C%20Jenop%20Global%20Healthcare%20Fund%20Ltd%2C%20Franklin%20Templeton%20Investment%20Funds%20-%20Biotechnology%20Discovery%20Fund%2C%20Franklin%20Strategic%20Series%20-%20Franklin%20Biotechnology%20Discovery%20Fund%2C%20funds%20managed%20by%20Franklin%20Resources%20Inc.%2C%20Pacific%20Select%20Fund%20-%20Health%20Sciences%20Portfolio%2C%20a%20fund%20managed%20by%20Pacific%20Life%20Insurance%20Co.%2C%20Asset%20Management%20Arm%2C%20Kevin%20Beck%2C%20El%20Chichon%20Partners%2C%20LLC%2C%20BioBrit%2C%20LLC%2C%20BMV%20Direct%20LP%2C%20Jon-Erik%20Borgen%2C%20Borgen%20Equity%20III%20Holdings%2C%20LLC%2C%20Jeffrey%20David%20Capello%2C%20DAFNA%20Life%20Science%20Ltd%2C%20DAFNA%20Life%20Science%20Market%20Neutral%20Ltd%2C%20DAFNA%20Life%20Science%20Select%20Ltd%2C%20Deerfield%20Special%20Situations%20Fund%2C%20L.P.%2C%20Deerfield%20Special%20Situations%20International%20Master%20Fund%2C%20L.P.%2C%20funds%20managed%20by%20Deerfield%20Capital%2C%20L.P.%2C%20EcoR1%20Capital%20Fund%2C%20L.P.%2C%20EcoR1%20Capital%20Fund%2C%20L.P.%2C%20Hunt-BioVentures%2C%20L.P.%2C%20Janus%20Global%20Life%20Sciences%20Fund%2C%20a%20fund%20managed%20by%20INTECH%20Investment%20Management%20LLC%20and%20Janus%20Capital%20Group%2C%20Inc.%2C%20Jennison%20Global%20Healthcare%20Master%20Fund%2C%20Ltd.%2C%20a%20fund%20managed%20by%20Jennison%20Associates%20LLC%2C%20Edward%20F.%20Keely%2C%20Patrick%20Lin%2C%20Thomas%20Malley%2C%20Prudential%20Sector%20Funds%20Inc-Prudential%20Health%20Sciences%20Fund.%20The%20company%20has%20received%20%2448%2C000%2C000%20in%20funding%20till%20date.%20The%20transaction%20is%20expected%20to%20close%20by%20March%2018%2C%202013.%20Leerink%20Swann%20LLC%20will%20act%20as%20lead%20placement%20agent%20and%20Ladenburg%20Thalmann%20%26%20Co.%20Inc.%2C%20Oppenheimer%20%26%20Co.%20Inc.%2C%20Roth%20Capital%20Partners%2C%20LLC%20and%20Wedbush%20Securities%20Inc.%20will%20act%20as%20co-agents%20to%20the%20company%20in%20connection%20with%20the%20transaction.%20The%20company%20intends%20to%20pay%20the%20placement%20agents%20a%20fee%20which%20equals%20to%206%25%20of%20the%20gross%20proceeds%20of%20the%20transaction.%20The%20company%20expects%20to%20pay%20placement%20agent%20fees%20of%20approximately%20%241%2C600%2C000%20to%20Leerink%20Swann%20LLC%20and%20an%20aggregate%20of%20approximately%20%24500%2C000%20to%20Ladenburg%20Thalmann%20%26%20Co.%20Inc.%2C%20Oppenheimer%20%26%20Co.%20Inc.%2C%20Roth%20Capital%20Partners%2C%20LLC%2C%20and%20Wedbush%20Securities%20Inc.%20Lia%20Der%20Marderosian%20of%20Wilmer%20Cutler%20Pickering%20Hale%20and%20Dorr%2C%20LLP%20will%20act%20as%20the%20legal%20advisor%20to%20the%20company.%20The%20securities%20will%20be%20issued%20pursuant%20to%20exemption%20provided%20under%20Regulation%20D.

OvaScience%2C%20Inc.%20%28OTCBB%3AOVSC%29%20announced%20a%20private%20placement%20of%203%2C888%2C880%20common%20shares%20at%20%249%20per%20share%20for%20gross%20proceeds%20of%20%2434%2C999%2C920%20on%20March%2012%2C%202013.%20The%20transaction%20will%20include%20participation%20from%20accredited%20investors%20including%20existing%20investors%20Blackwell%20Partners%2C%20LLC%2C%20Cycad%20Group%2C%20LLC%2C%20Hunt%20BioVentures%2C%20LP%2C%20Longwood%20Fund%2C%20LP%2C%20and%20RA%20Capital%20Healthcare%20Fund%2C%20LP%2C%20a%20fund%20managed%20by%20RA%20Capital%20Management%2C%20LLC%2C%20and%20new%20investors%20including%20Adage%20Capital%20Partners%2C%20L.P.%2C%20a%20fund%20managed%20by%20Adage%20Capital%20Management%2C%20L.P.%2C%20D3%20LifeScience%20Ltd.%2C%20Jenop%20Global%20Healthcare%20Fund%20Ltd%2C%20Franklin%20Templeton%20Investment%20Funds%20-%20Biotechnology%20Discovery%20Fund%2C%20Franklin%20Strategic%20Series%20-%20Franklin%20Biotechnology%20Discovery%20Fund%2C%20funds%20managed%20by%20Franklin%20Resources%20Inc.%2C%20Pacific%20Select%20Fund%20-%20Health%20Sciences%20Portfolio%2C%20a%20fund%20managed%20by%20Pacific%20Life%20Insurance%20Co.%2C%20Asset%20Management%20Arm%2C%20Kevin%20Beck%2C%20El%20Chichon%20Partners%2C%20LLC%2C%20BioBrit%2C%20LLC%2C%20BMV%20Direct%20LP%2C%20Jon-Erik%20Borgen%2C%20Borgen%20Equity%20III%20Holdings%2C%20LLC%2C%20Jeffrey%20David%20Capello%2C%20DAFNA%20Life%20Science%20Ltd%2C%20DAFNA%20Life%20Science%20Market%20Neutral%20Ltd%2C%20DAFNA%20Life%20Science%20Select%20Ltd%2C%20Deerfield%20Special%20Situations%20Fund%2C%20L.P.%2C%20Deerfield%20Special%20Situations%20International%20Master%20Fund%2C%20L.P.%2C%20funds%20managed%20by%20Deerfield%20Capital%2C%20L.P.%2C%20EcoR1%20Capital%20Fund%2C%20L.P.%2C%20EcoR1%20Capital%20Fund%2C%20L.P.%2C%20Hunt-BioVentures%2C%20L.P.%2C%20Janus%20Global%20Life%20Sciences%20Fund%2C%20a%20fund%20managed%20by%20INTECH%20Investment%20Management%20LLC%20and%20Janus%20Capital%20Group%2C%20Inc.%2C%20Jennison%20Global%20Healthcare%20Master%20Fund%2C%20Ltd.%2C%20a%20fund%20managed%20by%20Jennison%20Associates%20LLC%2C%20Edward%20F.%20Keely%2C%20Patrick%20Lin%2C%20Thomas%20Malley%2C%20Prudential%20Sector%20Funds%20Inc-Prudential%20Health%20Sciences%20Fund.%20The%20company%20has%20received%20%2448%2C000%2C000%20in%20funding%20till%20date.%20The%20transaction%20is%20expected%20to%20close%20by%20March%2018%2C%202013.%20Leerink%20Swann%20LLC%20will%20act%20as%20lead%20placement%20agent%20and%20Ladenburg%20Thalmann%20%26%20Co.%20Inc.%2C%20Oppenheimer%20%26%20Co.%20Inc.%2C%20Roth%20Capital%20Partners%2C%20LLC%20and%20Wedbush%20Securities%20Inc.%20will%20act%20as%20co-agents%20to%20the%20company%20in%20connection%20with%20the%20transaction.%20The%20company%20intends%20to%20pay%20the%20placement%20agents%20a%20fee%20which%20equals%20to%206%25%20of%20the%20gross%20proceeds%20of%20the%20transaction.%20The%20company%20expects%20to%20pay%20placement%20agent%20fees%20of%20approximately%20%241%2C600%2C000%20to%20Leerink%20Swann%20LLC%20and%20an%20aggregate%20of%20approximately%20%24500%2C000%20to%20Ladenburg%20Thalmann%20%26%20Co.%20Inc.%2C%20Oppenheimer%20%26%20Co.%20Inc.%2C%20Roth%20Capital%20Partners%2C%20LLC%2C%20and%20Wedbush%20Securities%20Inc.%20Lia%20Der%20Marderosian%20of%20Wilmer%20Cutler%20Pickering%20Hale%20and%20Dorr%2C%20LLP%20will%20act%20as%20the%20legal%20advisor%20to%20the%20company.%20The%20securities%20will%20be%20issued%20pursuant%20to%20exemption%20provided%20under%20Regulation%20D.

OvaScience%2C%20Inc.%20%28OTCBB%3AOVSC%29%20announced%20a%20private%20placement%20of%203%2C888%2C880%20common%20shares%20at%20%249%20per%20share%20for%20gross%20proceeds%20of%20%2434%2C999%2C920%20on%20March%2012%2C%202013.%20The%20transaction%20will%20include%20participation%20from%20accredited%20investors%20including%20existing%20investors%20Blackwell%20Partners%2C%20LLC%2C%20Cycad%20Group%2C%20LLC%2C%20Hunt%20BioVentures%2C%20LP%2C%20Longwood%20Fund%2C%20LP%2C%20and%20RA%20Capital%20Healthcare%20Fund%2C%20LP%2C%20a%20fund%20managed%20by%20RA%20Capital%20Management%2C%20LLC%2C%20and%20new%20investors%20including%20Adage%20Capital%20Partners%2C%20L.P.%2C%20a%20fund%20managed%20by%20Adage%20Capital%20Management%2C%20L.P.%2C%20D3%20LifeScience%20Ltd.%2C%20Jenop%20Global%20Healthcare%20Fund%20Ltd%2C%20Franklin%20Templeton%20Investment%20Funds%20-%20Biotechnology%20Discovery%20Fund%2C%20Franklin%20Strategic%20Series%20-%20Franklin%20Biotechnology%20Discovery%20Fund%2C%20funds%20managed%20by%20Franklin%20Resources%20Inc.%2C%20Pacific%20Select%20Fund%20-%20Health%20Sciences%20Portfolio%2C%20a%20fund%20managed%20by%20Pacific%20Life%20Insurance%20Co.%2C%20Asset%20Management%20Arm%2C%20Kevin%20Beck%2C%20El%20Chichon%20Partners%2C%20LLC%2C%20BioBrit%2C%20LLC%2C%20BMV%20Direct%20LP%2C%20Jon-Erik%20Borgen%2C%20Borgen%20Equity%20III%20Holdings%2C%20LLC%2C%20Jeffrey%20David%20Capello%2C%20DAFNA%20Life%20Science%20Ltd%2C%20DAFNA%20Life%20Science%20Market%20Neutral%20Ltd%2C%20DAFNA%20Life%20Science%20Select%20Ltd%2C%20Deerfield%20Special%20Situations%20Fund%2C%20L.P.%2C%20Deerfield%20Special%20Situations%20International%20Master%20Fund%2C%20L.P.%2C%20funds%20managed%20by%20Deerfield%20Capital%2C%20L.P.%2C%20EcoR1%20Capital%20Fund%2C%20L.P.%2C%20EcoR1%20Capital%20Fund%2C%20L.P.%2C%20Hunt-BioVentures%2C%20L.P.%2C%20Janus%20Global%20Life%20Sciences%20Fund%2C%20a%20fund%20managed%20by%20INTECH%20Investment%20Management%20LLC%20and%20Janus%20Capital%20Group%2C%20Inc.%2C%20Jennison%20Global%20Healthcare%20Master%20Fund%2C%20Ltd.%2C%20a%20fund%20managed%20by%20Jennison%20Associates%20LLC%2C%20Edward%20F.%20Keely%2C%20Patrick%20Lin%2C%20Thomas%20Malley%2C%20Prudential%20Sector%20Funds%20Inc-Prudential%20Health%20Sciences%20Fund.%20The%20company%20has%20received%20%2448%2C000%2C000%20in%20funding%20till%20date.%20The%20transaction%20is%20expected%20to%20close%20by%20March%2018%2C%202013.%20Leerink%20Swann%20LLC%20will%20act%20as%20lead%20placement%20agent%20and%20Ladenburg%20Thalmann%20%26%20Co.%20Inc.%2C%20Oppenheimer%20%26%20Co.%20Inc.%2C%20Roth%20Capital%20Partners%2C%20LLC%20and%20Wedbush%20Securities%20Inc.%20will%20act%20as%20co-agents%20to%20the%20company%20in%20connection%20with%20the%20transaction.%20The%20company%20intends%20to%20pay%20the%20placement%20agents%20a%20fee%20which%20equals%20to%206%25%20of%20the%20gross%20proceeds%20of%20the%20transaction.%20The%20company%20expects%20to%20pay%20placement%20agent%20fees%20of%20approximately%20%241%2C600%2C000%20to%20Leerink%20Swann%20LLC%20and%20an%20aggregate%20of%20approximately%20%24500%2C000%20to%20Ladenburg%20Thalmann%20%26%20Co.%20Inc.%2C%20Oppenheimer%20%26%20Co.%20Inc.%2C%20Roth%20Capital%20Partners%2C%20LLC%2C%20and%20Wedbush%20Securities%20Inc.%20Lia%20Der%20Marderosian%20of%20Wilmer%20Cutler%20Pickering%20Hale%20and%20Dorr%2C%20LLP%20will%20act%20as%20the%20legal%20advisor%20to%20the%20company.%20The%20securities%20will%20be%20issued%20pursuant%20to%20exemption%20provided%20under%20Regulation%20D.

OvaScience%2C%20Inc.%20%28OTCBB%3AOVSC%29%20announced%20a%20private%20placement%20of%203%2C888%2C880%20common%20shares%20at%20%249%20per%20share%20for%20gross%20proceeds%20of%20%2434%2C999%2C920%20on%20March%2012%2C%202013.%20The%20transaction%20will%20include%20participation%20from%20accredited%20investors%20including%20existing%20investors%20Blackwell%20Partners%2C%20LLC%2C%20Cycad%20Group%2C%20LLC%2C%20Hunt%20BioVentures%2C%20LP%2C%20Longwood%20Fund%2C%20LP%2C%20and%20RA%20Capital%20Healthcare%20Fund%2C%20LP%2C%20a%20fund%20managed%20by%20RA%20Capital%20Management%2C%20LLC%2C%20and%20new%20investors%20including%20Adage%20Capital%20Partners%2C%20L.P.%2C%20a%20fund%20managed%20by%20Adage%20Capital%20Management%2C%20L.P.%2C%20D3%20LifeScience%20Ltd.%2C%20Jenop%20Global%20Healthcare%20Fund%20Ltd%2C%20Franklin%20Templeton%20Investment%20Funds%20-%20Biotechnology%20Discovery%20Fund%2C%20Franklin%20Strategic%20Series%20-%20Franklin%20Biotechnology%20Discovery%20Fund%2C%20funds%20managed%20by%20Franklin%20Resources%20Inc.%2C%20Pacific%20Select%20Fund%20-%20Health%20Sciences%20Portfolio%2C%20a%20fund%20managed%20by%20Pacific%20Life%20Insurance%20Co.%2C%20Asset%20Management%20Arm%2C%20Kevin%20Beck%2C%20El%20Chichon%20Partners%2C%20LLC%2C%20BioBrit%2C%20LLC%2C%20BMV%20Direct%20LP%2C%20Jon-Erik%20Borgen%2C%20Borgen%20Equity%20III%20Holdings%2C%20LLC%2C%20Jeffrey%20David%20Capello%2C%20DAFNA%20Life%20Science%20Ltd%2C%20DAFNA%20Life%20Science%20Market%20Neutral%20Ltd%2C%20DAFNA%20Life%20Science%20Select%20Ltd%2C%20Deerfield%20Special%20Situations%20Fund%2C%20L.P.%2C%20Deerfield%20Special%20Situations%20International%20Master%20Fund%2C%20L.P.%2C%20funds%20managed%20by%20Deerfield%20Capital%2C%20L.P.%2C%20EcoR1%20Capital%20Fund%2C%20L.P.%2C%20EcoR1%20Capital%20Fund%2C%20L.P.%2C%20Hunt-BioVentures%2C%20L.P.%2C%20Janus%20Global%20Life%20Sciences%20Fund%2C%20a%20fund%20managed%20by%20INTECH%20Investment%20Management%20LLC%20and%20Janus%20Capital%20Group%2C%20Inc.%2C%20Jennison%20Global%20Healthcare%20Master%20Fund%2C%20Ltd.%2C%20a%20fund%20managed%20by%20Jennison%20Associates%20LLC%2C%20Edward%20F.%20Keely%2C%20Patrick%20Lin%2C%20Thomas%20Malley%2C%20Prudential%20Sector%20Funds%20Inc-Prudential%20Health%20Sciences%20Fund.%20The%20company%20has%20received%20%2448%2C000%2C000%20in%20funding%20till%20date.%20The%20transaction%20is%20expected%20to%20close%20by%20March%2018%2C%202013.%20Leerink%20Swann%20LLC%20will%20act%20as%20lead%20placement%20agent%20and%20Ladenburg%20Thalmann%20%26%20Co.%20Inc.%2C%20Oppenheimer%20%26%20Co.%20Inc.%2C%20Roth%20Capital%20Partners%2C%20LLC%20and%20Wedbush%20Securities%20Inc.%20will%20act%20as%20co-agents%20to%20the%20company%20in%20connection%20with%20the%20transaction.%20The%20company%20intends%20to%20pay%20the%20placement%20agents%20a%20fee%20which%20equals%20to%206%25%20of%20the%20gross%20proceeds%20of%20the%20transaction.%20The%20company%20expects%20to%20pay%20placement%20agent%20fees%20of%20approximately%20%241%2C600%2C000%20to%20Leerink%20Swann%20LLC%20and%20an%20aggregate%20of%20approximately%20%24500%2C000%20to%20Ladenburg%20Thalmann%20%26%20Co.%20Inc.%2C%20Oppenheimer%20%26%20Co.%20Inc.%2C%20Roth%20Capital%20Partners%2C%20LLC%2C%20and%20Wedbush%20Securities%20Inc.%20Lia%20Der%20Marderosian%20of%20Wilmer%20Cutler%20Pickering%20Hale%20and%20Dorr%2C%20LLP%20will%20act%20as%20the%20legal%20advisor%20to%20the%20company.%20The%20securities%20will%20be%20issued%20pursuant%20to%20exemption%20provided%20under%20Regulation%20D.

OvaScience%2C%20Inc.%20%28OTCBB%3AOVSC%29%20announced%20a%20private%20placement%20of%203%2C888%2C880%20common%20shares%20at%20%249%20per%20share%20for%20gross%20proceeds%20of%20%2434%2C999%2C920%20on%20March%2012%2C%202013.%20The%20transaction%20will%20include%20participation%20from%20accredited%20investors%20including%20existing%20investors%20Blackwell%20Partners%2C%20LLC%2C%20Cycad%20Group%2C%20LLC%2C%20Hunt%20BioVentures%2C%20LP%2C%20Longwood%20Fund%2C%20LP%2C%20and%20RA%20Capital%20Healthcare%20Fund%2C%20LP%2C%20a%20fund%20managed%20by%20RA%20Capital%20Management%2C%20LLC%2C%20and%20new%20investors%20including%20Adage%20Capital%20Partners%2C%20L.P.%2C%20a%20fund%20managed%20by%20Adage%20Capital%20Management%2C%20L.P.%2C%20D3%20LifeScience%20Ltd.%2C%20Jenop%20Global%20Healthcare%20Fund%20Ltd%2C%20Franklin%20Templeton%20Investment%20Funds%20-%20Biotechnology%20Discovery%20Fund%2C%20Franklin%20Strategic%20Series%20-%20Franklin%20Biotechnology%20Discovery%20Fund%2C%20funds%20managed%20by%20Franklin%20Resources%20Inc.%2C%20Pacific%20Select%20Fund%20-%20Health%20Sciences%20Portfolio%2C%20a%20fund%20managed%20by%20Pacific%20Life%20Insurance%20Co.%2C%20Asset%20Management%20Arm%2C%20Kevin%20Beck%2C%20El%20Chichon%20Partners%2C%20LLC%2C%20BioBrit%2C%20LLC%2C%20BMV%20Direct%20LP%2C%20Jon-Erik%20Borgen%2C%20Borgen%20Equity%20III%20Holdings%2C%20LLC%2C%20Jeffrey%20David%20Capello%2C%20DAFNA%20Life%20Science%20Ltd%2C%20DAFNA%20Life%20Science%20Market%20Neutral%20Ltd%2C%20DAFNA%20Life%20Science%20Select%20Ltd%2C%20Deerfield%20Special%20Situations%20Fund%2C%20L.P.%2C%20Deerfield%20Special%20Situations%20International%20Master%20Fund%2C%20L.P.%2C%20funds%20managed%20by%20Deerfield%20Capital%2C%20L.P.%2C%20EcoR1%20Capital%20Fund%2C%20L.P.%2C%20EcoR1%20Capital%20Fund%2C%20L.P.%2C%20Hunt-BioVentures%2C%20L.P.%2C%20Janus%20Global%20Life%20Sciences%20Fund%2C%20a%20fund%20managed%20by%20INTECH%20Investment%20Management%20LLC%20and%20Janus%20Capital%20Group%2C%20Inc.%2C%20Jennison%20Global%20Healthcare%20Master%20Fund%2C%20Ltd.%2C%20a%20fund%20managed%20by%20Jennison%20Associates%20LLC%2C%20Edward%20F.%20Keely%2C%20Patrick%20Lin%2C%20Thomas%20Malley%2C%20Prudential%20Sector%20Funds%20Inc-Prudential%20Health%20Sciences%20Fund.%20The%20company%20has%20received%20%2448%2C000%2C000%20in%20funding%20till%20date.%20The%20transaction%20is%20expected%20to%20close%20by%20March%2018%2C%202013.%20Leerink%20Swann%20LLC%20will%20act%20as%20lead%20placement%20agent%20and%20Ladenburg%20Thalmann%20%26%20Co.%20Inc.%2C%20Oppenheimer%20%26%20Co.%20Inc.%2C%20Roth%20Capital%20Partners%2C%20LLC%20and%20Wedbush%20Securities%20Inc.%20will%20act%20as%20co-agents%20to%20the%20company%20in%20connection%20with%20the%20transaction.%20The%20company%20intends%20to%20pay%20the%20placement%20agents%20a%20fee%20which%20equals%20to%206%25%20of%20the%20gross%20proceeds%20of%20the%20transaction.%20The%20company%20expects%20to%20pay%20placement%20agent%20fees%20of%20approximately%20%241%2C600%2C000%20to%20Leerink%20Swann%20LLC%20and%20an%20aggregate%20of%20approximately%20%24500%2C000%20to%20Ladenburg%20Thalmann%20%26%20Co.%20Inc.%2C%20Oppenheimer%20%26%20Co.%20Inc.%2C%20Roth%20Capital%20Partners%2C%20LLC%2C%20and%20Wedbush%20Securities%20Inc.%20Lia%20Der%20Marderosian%20of%20Wilmer%20Cutler%20Pickering%20Hale%20and%20Dorr%2C%20LLP%20will%20act%20as%20the%20legal%20advisor%20to%20the%20company.%20The%20securities%20will%20be%20issued%20pursuant%20to%20exemption%20provided%20under%20Regulation%20D.

OvaScience%2C%20Inc.%20%28OTCBB%3AOVSC%29%20announced%20a%20private%20placement%20of%203%2C888%2C880%20common%20shares%20at%20%249%20per%20share%20for%20gross%20proceeds%20of%20%2434%2C999%2C920%20on%20March%2012%2C%202013.%20The%20transaction%20will%20include%20participation%20from%20accredited%20investors%20including%20existing%20investors%20Blackwell%20Partners%2C%20LLC%2C%20Cycad%20Group%2C%20LLC%2C%20Hunt%20BioVentures%2C%20LP%2C%20Longwood%20Fund%2C%20LP%2C%20and%20RA%20Capital%20Healthcare%20Fund%2C%20LP%2C%20a%20fund%20managed%20by%20RA%20Capital%20Management%2C%20LLC%2C%20and%20new%20investors%20including%20Adage%20Capital%20Partners%2C%20L.P.%2C%20a%20fund%20managed%20by%20Adage%20Capital%20Management%2C%20L.P.%2C%20D3%20LifeScience%20Ltd.%2C%20Jenop%20Global%20Healthcare%20Fund%20Ltd%2C%20Franklin%20Templeton%20Investment%20Funds%20-%20Biotechnology%20Discovery%20Fund%2C%20Franklin%20Strategic%20Series%20-%20Franklin%20Biotechnology%20Discovery%20Fund%2C%20funds%20managed%20by%20Franklin%20Resources%20Inc.%2C%20Pacific%20Select%20Fund%20-%20Health%20Sciences%20Portfolio%2C%20a%20fund%20managed%20by%20Pacific%20Life%20Insurance%20Co.%2C%20Asset%20Management%20Arm%2C%20Kevin%20Beck%2C%20El%20Chichon%20Partners%2C%20LLC%2C%20BioBrit%2C%20LLC%2C%20BMV%20Direct%20LP%2C%20Jon-Erik%20Borgen%2C%20Borgen%20Equity%20III%20Holdings%2C%20LLC%2C%20Jeffrey%20David%20Capello%2C%20DAFNA%20Life%20Science%20Ltd%2C%20DAFNA%20Life%20Science%20Market%20Neutral%20Ltd%2C%20DAFNA%20Life%20Science%20Select%20Ltd%2C%20Deerfield%20Special%20Situations%20Fund%2C%20L.P.%2C%20Deerfield%20Special%20Situations%20International%20Master%20Fund%2C%20L.P.%2C%20funds%20managed%20by%20Deerfield%20Capital%2C%20L.P.%2C%20EcoR1%20Capital%20Fund%2C%20L.P.%2C%20EcoR1%20Capital%20Fund%2C%20L.P.%2C%20Hunt-BioVentures%2C%20L.P.%2C%20Janus%20Global%20Life%20Sciences%20Fund%2C%20a%20fund%20managed%20by%20INTECH%20Investment%20Management%20LLC%20and%20Janus%20Capital%20Group%2C%20Inc.%2C%20Jennison%20Global%20Healthcare%20Master%20Fund%2C%20Ltd.%2C%20a%20fund%20managed%20by%20Jennison%20Associates%20LLC%2C%20Edward%20F.%20Keely%2C%20Patrick%20Lin%2C%20Thomas%20Malley%2C%20Prudential%20Sector%20Funds%20Inc-Prudential%20Health%20Sciences%20Fund.%20The%20company%20has%20received%20%2448%2C000%2C000%20in%20funding%20till%20date.%20The%20transaction%20is%20expected%20to%20close%20by%20March%2018%2C%202013.%20Leerink%20Swann%20LLC%20will%20act%20as%20lead%20placement%20agent%20and%20Ladenburg%20Thalmann%20%26%20Co.%20Inc.%2C%20Oppenheimer%20%26%20Co.%20Inc.%2C%20Roth%20Capital%20Partners%2C%20LLC%20and%20Wedbush%20Securities%20Inc.%20will%20act%20as%20co-agents%20to%20the%20company%20in%20connection%20with%20the%20transaction.%20The%20company%20intends%20to%20pay%20the%20placement%20agents%20a%20fee%20which%20equals%20to%206%25%20of%20the%20gross%20proceeds%20of%20the%20transaction.%20The%20company%20expects%20to%20pay%20placement%20agent%20fees%20of%20approximately%20%241%2C600%2C000%20to%20Leerink%20Swann%20LLC%20and%20an%20aggregate%20of%20approximately%20%24500%2C000%20to%20Ladenburg%20Thalmann%20%26%20Co.%20Inc.%2C%20Oppenheimer%20%26%20Co.%20Inc.%2C%20Roth%20Capital%20Partners%2C%20LLC%2C%20and%20Wedbush%20Securities%20Inc.%20Lia%20Der%20Marderosian%20of%20Wilmer%20Cutler%20Pickering%20Hale%20and%20Dorr%2C%20LLP%20will%20act%20as%20the%20legal%20advisor%20to%20the%20company.%20The%20securities%20will%20be%20issued%20pursuant%20to%20exemption%20provided%20under%20Regulation%20D.

OvaScience%2C%20Inc.%20%28OTCBB%3AOVSC%29%20announced%20a%20private%20placement%20of%203%2C888%2C880%20common%20shares%20at%20%249%20per%20share%20for%20gross%20proceeds%20of%20%2434%2C999%2C920%20on%20March%2012%2C%202013.%20The%20transaction%20will%20include%20participation%20from%20accredited%20investors%20including%20existing%20investors%20Blackwell%20Partners%2C%20LLC%2C%20Cycad%20Group%2C%20LLC%2C%20Hunt%20BioVentures%2C%20LP%2C%20Longwood%20Fund%2C%20LP%2C%20and%20RA%20Capital%20Healthcare%20Fund%2C%20LP%2C%20a%20fund%20managed%20by%20RA%20Capital%20Management%2C%20LLC%2C%20and%20new%20investors%20including%20Adage%20Capital%20Partners%2C%20L.P.%2C%20a%20fund%20managed%20by%20Adage%20Capital%20Management%2C%20L.P.%2C%20D3%20LifeScience%20Ltd.%2C%20Jenop%20Global%20Healthcare%20Fund%20Ltd%2C%20Franklin%20Templeton%20Investment%20Funds%20-%20Biotechnology%20Discovery%20Fund%2C%20Franklin%20Strategic%20Series%20-%20Franklin%20Biotechnology%20Discovery%20Fund%2C%20funds%20managed%20by%20Franklin%20Resources%20Inc.%2C%20Pacific%20Select%20Fund%20-%20Health%20Sciences%20Portfolio%2C%20a%20fund%20managed%20by%20Pacific%20Life%20Insurance%20Co.%2C%20Asset%20Management%20Arm%2C%20Kevin%20Beck%2C%20El%20Chichon%20Partners%2C%20LLC%2C%20BioBrit%2C%20LLC%2C%20BMV%20Direct%20LP%2C%20Jon-Erik%20Borgen%2C%20Borgen%20Equity%20III%20Holdings%2C%20LLC%2C%20Jeffrey%20David%20Capello%2C%20DAFNA%20Life%20Science%20Ltd%2C%20DAFNA%20Life%20Science%20Market%20Neutral%20Ltd%2C%20DAFNA%20Life%20Science%20Select%20Ltd%2C%20Deerfield%20Special%20Situations%20Fund%2C%20L.P.%2C%20Deerfield%20Special%20Situations%20International%20Master%20Fund%2C%20L.P.%2C%20funds%20managed%20by%20Deerfield%20Capital%2C%20L.P.%2C%20EcoR1%20Capital%20Fund%2C%20L.P.%2C%20EcoR1%20Capital%20Fund%2C%20L.P.%2C%20Hunt-BioVentures%2C%20L.P.%2C%20Janus%20Global%20Life%20Sciences%20Fund%2C%20a%20fund%20managed%20by%20INTECH%20Investment%20Management%20LLC%20and%20Janus%20Capital%20Group%2C%20Inc.%2C%20Jennison%20Global%20Healthcare%20Master%20Fund%2C%20Ltd.%2C%20a%20fund%20managed%20by%20Jennison%20Associates%20LLC%2C%20Edward%20F.%20Keely%2C%20Patrick%20Lin%2C%20Thomas%20Malley%2C%20Prudential%20Sector%20Funds%20Inc-Prudential%20Health%20Sciences%20Fund.%20The%20company%20has%20received%20%2448%2C000%2C000%20in%20funding%20till%20date.%20The%20transaction%20is%20expected%20to%20close%20by%20March%2018%2C%202013.%20Leerink%20Swann%20LLC%20will%20act%20as%20lead%20placement%20agent%20and%20Ladenburg%20Thalmann%20%26%20Co.%20Inc.%2C%20Oppenheimer%20%26%20Co.%20Inc.%2C%20Roth%20Capital%20Partners%2C%20LLC%20and%20Wedbush%20Securities%20Inc.%20will%20act%20as%20co-agents%20to%20the%20company%20in%20connection%20with%20the%20transaction.%20The%20company%20intends%20to%20pay%20the%20placement%20agents%20a%20fee%20which%20equals%20to%206%25%20of%20the%20gross%20proceeds%20of%20the%20transaction.%20The%20company%20expects%20to%20pay%20placement%20agent%20fees%20of%20approximately%20%241%2C600%2C000%20to%20Leerink%20Swann%20LLC%20and%20an%20aggregate%20of%20approximately%20%24500%2C000%20to%20Ladenburg%20Thalmann%20%26%20Co.%20Inc.%2C%20Oppenheimer%20%26%20Co.%20Inc.%2C%20Roth%20Capital%20Partners%2C%20LLC%2C%20and%20Wedbush%20Securities%20Inc.%20Lia%20Der%20Marderosian%20of%20Wilmer%20Cutler%20Pickering%20Hale%20and%20Dorr%2C%20LLP%20will%20act%20as%20the%20legal%20advisor%20to%20the%20company.%20The%20securities%20will%20be%20issued%20pursuant%20to%20exemption%20provided%20under%20Regulation%20D.

OvaScience%2C%20Inc.%20%28OTCBB%3AOVSC%29%20announced%20a%20private%20placement%20of%203%2C888%2C880%20common%20shares%20at%20%249%20per%20share%20for%20gross%20proceeds%20of%20%2434%2C999%2C920%20on%20March%2012%2C%202013.%20The%20transaction%20will%20include%20participation%20from%20accredited%20investors%20including%20existing%20investors%20Blackwell%20Partners%2C%20LLC%2C%20Cycad%20Group%2C%20LLC%2C%20Hunt%20BioVentures%2C%20LP%2C%20Longwood%20Fund%2C%20LP%2C%20and%20RA%20Capital%20Healthcare%20Fund%2C%20LP%2C%20a%20fund%20managed%20by%20RA%20Capital%20Management%2C%20LLC%2C%20and%20new%20investors%20including%20Adage%20Capital%20Partners%2C%20L.P.%2C%20a%20fund%20managed%20by%20Adage%20Capital%20Management%2C%20L.P.%2C%20D3%20LifeScience%20Ltd.%2C%20Jenop%20Global%20Healthcare%20Fund%20Ltd%2C%20Franklin%20Templeton%20Investment%20Funds%20-%20Biotechnology%20Discovery%20Fund%2C%20Franklin%20Strategic%20Series%20-%20Franklin%20Biotechnology%20Discovery%20Fund%2C%20funds%20managed%20by%20Franklin%20Resources%20Inc.%2C%20Pacific%20Select%20Fund%20-%20Health%20Sciences%20Portfolio%2C%20a%20fund%20managed%20by%20Pacific%20Life%20Insurance%20Co.%2C%20Asset%20Management%20Arm%2C%20Kevin%20Beck%2C%20El%20Chichon%20Partners%2C%20LLC%2C%20BioBrit%2C%20LLC%2C%20BMV%20Direct%20LP%2C%20Jon-Erik%20Borgen%2C%20Borgen%20Equity%20III%20Holdings%2C%20LLC%2C%20Jeffrey%20David%20Capello%2C%20DAFNA%20Life%20Science%20Ltd%2C%20DAFNA%20Life%20Science%20Market%20Neutral%20Ltd%2C%20DAFNA%20Life%20Science%20Select%20Ltd%2C%20Deerfield%20Special%20Situations%20Fund%2C%20L.P.%2C%20Deerfield%20Special%20Situations%20International%20Master%20Fund%2C%20L.P.%2C%20funds%20managed%20by%20Deerfield%20Capital%2C%20L.P.%2C%20EcoR1%20Capital%20Fund%2C%20L.P.%2C%20EcoR1%20Capital%20Fund%2C%20L.P.%2C%20Hunt-BioVentures%2C%20L.P.%2C%20Janus%20Global%20Life%20Sciences%20Fund%2C%20a%20fund%20managed%20by%20INTECH%20Investment%20Management%20LLC%20and%20Janus%20Capital%20Group%2C%20Inc.%2C%20Jennison%20Global%20Healthcare%20Master%20Fund%2C%20Ltd.%2C%20a%20fund%20managed%20by%20Jennison%20Associates%20LLC%2C%20Edward%20F.%20Keely%2C%20Patrick%20Lin%2C%20Thomas%20Malley%2C%20Prudential%20Sector%20Funds%20Inc-Prudential%20Health%20Sciences%20Fund.%20The%20company%20has%20received%20%2448%2C000%2C000%20in%20funding%20till%20date.%20The%20transaction%20is%20expected%20to%20close%20by%20March%2018%2C%202013.%20Leerink%20Swann%20LLC%20will%20act%20as%20lead%20placement%20agent%20and%20Ladenburg%20Thalmann%20%26%20Co.%20Inc.%2C%20Oppenheimer%20%26%20Co.%20Inc.%2C%20Roth%20Capital%20Partners%2C%20LLC%20and%20Wedbush%20Securities%20Inc.%20will%20act%20as%20co-agents%20to%20the%20company%20in%20connection%20with%20the%20transaction.%20The%20company%20intends%20to%20pay%20the%20placement%20agents%20a%20fee%20which%20equals%20to%206%25%20of%20the%20gross%20proceeds%20of%20the%20transaction.%20The%20company%20expects%20to%20pay%20placement%20agent%20fees%20of%20approximately%20%241%2C600%2C000%20to%20Leerink%20Swann%20LLC%20and%20an%20aggregate%20of%20approximately%20%24500%2C000%20to%20Ladenburg%20Thalmann%20%26%20Co.%20Inc.%2C%20Oppenheimer%20%26%20Co.%20Inc.%2C%20Roth%20Capital%20Partners%2C%20LLC%2C%20and%20Wedbush%20Securities%20Inc.%20Lia%20Der%20Marderosian%20of%20Wilmer%20Cutler%20Pickering%20Hale%20and%20Dorr%2C%20LLP%20will%20act%20as%20the%20legal%20advisor%20to%20the%20company.%20The%20securities%20will%20be%20issued%20pursuant%20to%20exemption%20provided%20under%20Regulation%20D.

OvaScience%2C%20Inc.%20%28OTCBB%3AOVSC%29%20announced%20a%20private%20placement%20of%203%2C888%2C880%20common%20shares%20at%20%249%20per%20share%20for%20gross%20proceeds%20of%20%2434%2C999%2C920%20on%20March%2012%2C%202013.%20The%20transaction%20will%20include%20participation%20from%20accredited%20investors%20including%20existing%20investors%20Blackwell%20Partners%2C%20LLC%2C%20Cycad%20Group%2C%20LLC%2C%20Hunt%20BioVentures%2C%20LP%2C%20Longwood%20Fund%2C%20LP%2C%20and%20RA%20Capital%20Healthcare%20Fund%2C%20LP%2C%20a%20fund%20managed%20by%20RA%20Capital%20Management%2C%20LLC%2C%20and%20new%20investors%20including%20Adage%20Capital%20Partners%2C%20L.P.%2C%20a%20fund%20managed%20by%20Adage%20Capital%20Management%2C%20L.P.%2C%20D3%20LifeScience%20Ltd.%2C%20Jenop%20Global%20Healthcare%20Fund%20Ltd%2C%20Franklin%20Templeton%20Investment%20Funds%20-%20Biotechnology%20Discovery%20Fund%2C%20Franklin%20Strategic%20Series%20-%20Franklin%20Biotechnology%20Discovery%20Fund%2C%20funds%20managed%20by%20Franklin%20Resources%20Inc.%2C%20Pacific%20Select%20Fund%20-%20Health%20Sciences%20Portfolio%2C%20a%20fund%20managed%20by%20Pacific%20Life%20Insurance%20Co.%2C%20Asset%20Management%20Arm%2C%20Kevin%20Beck%2C%20El%20Chichon%20Partners%2C%20LLC%2C%20BioBrit%2C%20LLC%2C%20BMV%20Direct%20LP%2C%20Jon-Erik%20Borgen%2C%20Borgen%20Equity%20III%20Holdings%2C%20LLC%2C%20Jeffrey%20David%20Capello%2C%20DAFNA%20Life%20Science%20Ltd%2C%20DAFNA%20Life%20Science%20Market%20Neutral%20Ltd%2C%20DAFNA%20Life%20Science%20Select%20Ltd%2C%20Deerfield%20Special%20Situations%20Fund%2C%20L.P.%2C%20Deerfield%20Special%20Situations%20International%20Master%20Fund%2C%20L.P.%2C%20funds%20managed%20by%20Deerfield%20Capital%2C%20L.P.%2C%20EcoR1%20Capital%20Fund%2C%20L.P.%2C%20EcoR1%20Capital%20Fund%2C%20L.P.%2C%20Hunt-BioVentures%2C%20L.P.%2C%20Janus%20Global%20Life%20Sciences%20Fund%2C%20a%20fund%20managed%20by%20INTECH%20Investment%20Management%20LLC%20and%20Janus%20Capital%20Group%2C%20Inc.%2C%20Jennison%20Global%20Healthcare%20Master%20Fund%2C%20Ltd.%2C%20a%20fund%20managed%20by%20Jennison%20Associates%20LLC%2C%20Edward%20F.%20Keely%2C%20Patrick%20Lin%2C%20Thomas%20Malley%2C%20Prudential%20Sector%20Funds%20Inc-Prudential%20Health%20Sciences%20Fund.%20The%20company%20has%20received%20%2448%2C000%2C000%20in%20funding%20till%20date.%20The%20transaction%20is%20expected%20to%20close%20by%20March%2018%2C%202013.%20Leerink%20Swann%20LLC%20will%20act%20as%20lead%20placement%20agent%20and%20Ladenburg%20Thalmann%20%26%20Co.%20Inc.%2C%20Oppenheimer%20%26%20Co.%20Inc.%2C%20Roth%20Capital%20Partners%2C%20LLC%20and%20Wedbush%20Securities%20Inc.%20will%20act%20as%20co-agents%20to%20the%20company%20in%20connection%20with%20the%20transaction.%20The%20company%20intends%20to%20pay%20the%20placement%20agents%20a%20fee%20which%20equals%20to%206%25%20of%20the%20gross%20proceeds%20of%20the%20transaction.%20The%20company%20expects%20to%20pay%20placement%20agent%20fees%20of%20approximately%20%241%2C600%2C000%20to%20Leerink%20Swann%20LLC%20and%20an%20aggregate%20of%20approximately%20%24500%2C000%20to%20Ladenburg%20Thalmann%20%26%20Co.%20Inc.%2C%20Oppenheimer%20%26%20Co.%20Inc.%2C%20Roth%20Capital%20Partners%2C%20LLC%2C%20and%20Wedbush%20Securities%20Inc.%20Lia%20Der%20Marderosian%20of%20Wilmer%20Cutler%20Pickering%20Hale%20and%20Dorr%2C%20LLP%20will%20act%20as%20the%20legal%20advisor%20to%20the%20company.%20The%20securities%20will%20be%20issued%20pursuant%20to%20exemption%20provided%20under%20Regulation%20D.

OvaScience%2C%20Inc.%20%28OTCBB%3AOVSC%29%20announced%20a%20private%20placement%20of%203%2C888%2C880%20common%20shares%20at%20%249%20per%20share%20for%20gross%20proceeds%20of%20%2434%2C999%2C920%20on%20March%2012%2C%202013.%20The%20transaction%20will%20include%20participation%20from%20accredited%20investors%20including%20existing%20investors%20Blackwell%20Partners%2C%20LLC%2C%20Cycad%20Group%2C%20LLC%2C%20Hunt%20BioVentures%2C%20LP%2C%20Longwood%20Fund%2C%20LP%2C%20and%20RA%20Capital%20Healthcare%20Fund%2C%20LP%2C%20a%20fund%20managed%20by%20RA%20Capital%20Management%2C%20LLC%2C%20and%20new%20investors%20including%20Adage%20Capital%20Partners%2C%20L.P.%2C%20a%20fund%20managed%20by%20Adage%20Capital%20Management%2C%20L.P.%2C%20D3%20LifeScience%20Ltd.%2C%20Jenop%20Global%20Healthcare%20Fund%20Ltd%2C%20Franklin%20Templeton%20Investment%20Funds%20-%20Biotechnology%20Discovery%20Fund%2C%20Franklin%20Strategic%20Series%20-%20Franklin%20Biotechnology%20Discovery%20Fund%2C%20funds%20managed%20by%20Franklin%20Resources%20Inc.%2C%20Pacific%20Select%20Fund%20-%20Health%20Sciences%20Portfolio%2C%20a%20fund%20managed%20by%20Pacific%20Life%20Insurance%20Co.%2C%20Asset%20Management%20Arm%2C%20Kevin%20Beck%2C%20El%20Chichon%20Partners%2C%20LLC%2C%20BioBrit%2C%20LLC%2C%20BMV%20Direct%20LP%2C%20Jon-Erik%20Borgen%2C%20Borgen%20Equity%20III%20Holdings%2C%20LLC%2C%20Jeffrey%20David%20Capello%2C%20DAFNA%20Life%20Science%20Ltd%2C%20DAFNA%20Life%20Science%20Market%20Neutral%20Ltd%2C%20DAFNA%20Life%20Science%20Select%20Ltd%2C%20Deerfield%20Special%20Situations%20Fund%2C%20L.P.%2C%20Deerfield%20Special%20Situations%20International%20Master%20Fund%2C%20L.P.%2C%20funds%20managed%20by%20Deerfield%20Capital%2C%20L.P.%2C%20EcoR1%20Capital%20Fund%2C%20L.P.%2C%20EcoR1%20Capital%20Fund%2C%20L.P.%2C%20Hunt-BioVentures%2C%20L.P.%2C%20Janus%20Global%20Life%20Sciences%20Fund%2C%20a%20fund%20managed%20by%20INTECH%20Investment%20Management%20LLC%20and%20Janus%20Capital%20Group%2C%20Inc.%2C%20Jennison%20Global%20Healthcare%20Master%20Fund%2C%20Ltd.%2C%20a%20fund%20managed%20by%20Jennison%20Associates%20LLC%2C%20Edward%20F.%20Keely%2C%20Patrick%20Lin%2C%20Thomas%20Malley%2C%20Prudential%20Sector%20Funds%20Inc-Prudential%20Health%20Sciences%20Fund.%20The%20company%20has%20received%20%2448%2C000%2C000%20in%20funding%20till%20date.%20The%20transaction%20is%20expected%20to%20close%20by%20March%2018%2C%202013.%20Leerink%20Swann%20LLC%20will%20act%20as%20lead%20placement%20agent%20and%20Ladenburg%20Thalmann%20%26%20Co.%20Inc.%2C%20Oppenheimer%20%26%20Co.%20Inc.%2C%20Roth%20Capital%20Partners%2C%20LLC%20and%20Wedbush%20Securities%20Inc.%20will%20act%20as%20co-agents%20to%20the%20company%20in%20connection%20with%20the%20transaction.%20The%20company%20intends%20to%20pay%20the%20placement%20agents%20a%20fee%20which%20equals%20to%206%25%20of%20the%20gross%20proceeds%20of%20the%20transaction.%20The%20company%20expects%20to%20pay%20placement%20agent%20fees%20of%20approximately%20%241%2C600%2C000%20to%20Leerink%20Swann%20LLC%20and%20an%20aggregate%20of%20approximately%20%24500%2C000%20to%20Ladenburg%20Thalmann%20%26%20Co.%20Inc.%2C%20Oppenheimer%20%26%20Co.%20Inc.%2C%20Roth%20Capital%20Partners%2C%20LLC%2C%20and%20Wedbush%20Securities%20Inc.%20Lia%20Der%20Marderosian%20of%20Wilmer%20Cutler%20Pickering%20Hale%20and%20Dorr%2C%20LLP%20will%20act%20as%20the%20legal%20advisor%20to%20the%20company.%20The%20securities%20will%20be%20issued%20pursuant%20to%20exemption%20provided%20under%20Regulation%20D.

OvaScience%2C%20Inc.%20%28OTCBB%3AOVSC%29%20announced%20a%20private%20placement%20of%203%2C888%2C880%20common%20shares%20at%20%249%20per%20share%20for%20gross%20proceeds%20of%20%2434%2C999%2C920%20on%20March%2012%2C%202013.%20The%20transaction%20will%20include%20participation%20from%20accredited%20investors%20including%20existing%20investors%20Blackwell%20Partners%2C%20LLC%2C%20Cycad%20Group%2C%20LLC%2C%20Hunt%20BioVentures%2C%20LP%2C%20Longwood%20Fund%2C%20LP%2C%20and%20RA%20Capital%20Healthcare%20Fund%2C%20LP%2C%20a%20fund%20managed%20by%20RA%20Capital%20Management%2C%20LLC%2C%20and%20new%20investors%20including%20Adage%20Capital%20Partners%2C%20L.P.%2C%20a%20fund%20managed%20by%20Adage%20Capital%20Management%2C%20L.P.%2C%20D3%20LifeScience%20Ltd.%2C%20Jenop%20Global%20Healthcare%20Fund%20Ltd%2C%20Franklin%20Templeton%20Investment%20Funds%20-%20Biotechnology%20Discovery%20Fund%2C%20Franklin%20Strategic%20Series%20-%20Franklin%20Biotechnology%20Discovery%20Fund%2C%20funds%20managed%20by%20Franklin%20Resources%20Inc.%2C%20Pacific%20Select%20Fund%20-%20Health%20Sciences%20Portfolio%2C%20a%20fund%20managed%20by%20Pacific%20Life%20Insurance%20Co.%2C%20Asset%20Management%20Arm%2C%20Kevin%20Beck%2C%20El%20Chichon%20Partners%2C%20LLC%2C%20BioBrit%2C%20LLC%2C%20BMV%20Direct%20LP%2C%20Jon-Erik%20Borgen%2C%20Borgen%20Equity%20III%20Holdings%2C%20LLC%2C%20Jeffrey%20David%20Capello%2C%20DAFNA%20Life%20Science%20Ltd%2C%20DAFNA%20Life%20Science%20Market%20Neutral%20Ltd%2C%20DAFNA%20Life%20Science%20Select%20Ltd%2C%20Deerfield%20Special%20Situations%20Fund%2C%20L.P.%2C%20Deerfield%20Special%20Situations%20International%20Master%20Fund%2C%20L.P.%2C%20funds%20managed%20by%20Deerfield%20Capital%2C%20L.P.%2C%20EcoR1%20Capital%20Fund%2C%20L.P.%2C%20EcoR1%20Capital%20Fund%2C%20L.P.%2C%20Hunt-BioVentures%2C%20L.P.%2C%20Janus%20Global%20Life%20Sciences%20Fund%2C%20a%20fund%20managed%20by%20INTECH%20Investment%20Management%20LLC%20and%20Janus%20Capital%20Group%2C%20Inc.%2C%20Jennison%20Global%20Healthcare%20Master%20Fund%2C%20Ltd.%2C%20a%20fund%20managed%20by%20Jennison%20Associates%20LLC%2C%20Edward%20F.%20Keely%2C%20Patrick%20Lin%2C%20Thomas%20Malley%2C%20Prudential%20Sector%20Funds%20Inc-Prudential%20Health%20Sciences%20Fund.%20The%20company%20has%20received%20%2448%2C000%2C000%20in%20funding%20till%20date.%20The%20transaction%20is%20expected%20to%20close%20by%20March%2018%2C%202013.%20Leerink%20Swann%20LLC%20will%20act%20as%20lead%20placement%20agent%20and%20Ladenburg%20Thalmann%20%26%20Co.%20Inc.%2C%20Oppenheimer%20%26%20Co.%20Inc.%2C%20Roth%20Capital%20Partners%2C%20LLC%20and%20Wedbush%20Securities%20Inc.%20will%20act%20as%20co-agents%20to%20the%20company%20in%20connection%20with%20the%20transaction.%20The%20company%20intends%20to%20pay%20the%20placement%20agents%20a%20fee%20which%20equals%20to%206%25%20of%20the%20gross%20proceeds%20of%20the%20transaction.%20The%20company%20expects%20to%20pay%20placement%20agent%20fees%20of%20approximately%20%241%2C600%2C000%20to%20Leerink%20Swann%20LLC%20and%20an%20aggregate%20of%20approximately%20%24500%2C000%20to%20Ladenburg%20Thalmann%20%26%20Co.%20Inc.%2C%20Oppenheimer%20%26%20Co.%20Inc.%2C%20Roth%20Capital%20Partners%2C%20LLC%2C%20and%20Wedbush%20Securities%20Inc.%20Lia%20Der%20Marderosian%20of%20Wilmer%20Cutler%20Pickering%20Hale%20and%20Dorr%2C%20LLP%20will%20act%20as%20the%20legal%20advisor%20to%20the%20company.%20The%20securities%20will%20be%20issued%20pursuant%20to%20exemption%20provided%20under%20Regulation%20D.

OvaScience%2C%20Inc.%20%28OTCBB%3AOVSC%29%20announced%20a%20private%20placement%20of%203%2C888%2C880%20common%20shares%20at%20%249%20per%20share%20for%20gross%20proceeds%20of%20%2434%2C999%2C920%20on%20March%2012%2C%202013.%20The%20transaction%20will%20include%20participation%20from%20accredited%20investors%20including%20existing%20investors%20Blackwell%20Partners%2C%20LLC%2C%20Cycad%20Group%2C%20LLC%2C%20Hunt%20BioVentures%2C%20LP%2C%20Longwood%20Fund%2C%20LP%2C%20and%20RA%20Capital%20Healthcare%20Fund%2C%20LP%2C%20a%20fund%20managed%20by%20RA%20Capital%20Management%2C%20LLC%2C%20and%20new%20investors%20including%20Adage%20Capital%20Partners%2C%20L.P.%2C%20a%20fund%20managed%20by%20Adage%20Capital%20Management%2C%20L.P.%2C%20D3%20LifeScience%20Ltd.%2C%20Jenop%20Global%20Healthcare%20Fund%20Ltd%2C%20Franklin%20Templeton%20Investment%20Funds%20-%20Biotechnology%20Discovery%20Fund%2C%20Franklin%20Strategic%20Series%20-%20Franklin%20Biotechnology%20Discovery%20Fund%2C%20funds%20managed%20by%20Franklin%20Resources%20Inc.%2C%20Pacific%20Select%20Fund%20-%20Health%20Sciences%20Portfolio%2C%20a%20fund%20managed%20by%20Pacific%20Life%20Insurance%20Co.%2C%20Asset%20Management%20Arm%2C%20Kevin%20Beck%2C%20El%20Chichon%20Partners%2C%20LLC%2C%20BioBrit%2C%20LLC%2C%20BMV%20Direct%20LP%2C%20Jon-Erik%20Borgen%2C%20Borgen%20Equity%20III%20Holdings%2C%20LLC%2C%20Jeffrey%20David%20Capello%2C%20DAFNA%20Life%20Science%20Ltd%2C%20DAFNA%20Life%20Science%20Market%20Neutral%20Ltd%2C%20DAFNA%20Life%20Science%20Select%20Ltd%2C%20Deerfield%20Special%20Situations%20Fund%2C%20L.P.%2C%20Deerfield%20Special%20Situations%20International%20Master%20Fund%2C%20L.P.%2C%20funds%20managed%20by%20Deerfield%20Capital%2C%20L.P.%2C%20EcoR1%20Capital%20Fund%2C%20L.P.%2C%20EcoR1%20Capital%20Fund%2C%20L.P.%2C%20Hunt-BioVentures%2C%20L.P.%2C%20Janus%20Global%20Life%20Sciences%20Fund%2C%20a%20fund%20managed%20by%20INTECH%20Investment%20Management%20LLC%20and%20Janus%20Capital%20Group%2C%20Inc.%2C%20Jennison%20Global%20Healthcare%20Master%20Fund%2C%20Ltd.%2C%20a%20fund%20managed%20by%20Jennison%20Associates%20LLC%2C%20Edward%20F.%20Keely%2C%20Patrick%20Lin%2C%20Thomas%20Malley%2C%20Prudential%20Sector%20Funds%20Inc-Prudential%20Health%20Sciences%20Fund.%20The%20company%20has%20received%20%2448%2C000%2C000%20in%20funding%20till%20date.%20The%20transaction%20is%20expected%20to%20close%20by%20March%2018%2C%202013.%20Leerink%20Swann%20LLC%20will%20act%20as%20lead%20placement%20agent%20and%20Ladenburg%20Thalmann%20%26%20Co.%20Inc.%2C%20Oppenheimer%20%26%20Co.%20Inc.%2C%20Roth%20Capital%20Partners%2C%20LLC%20and%20Wedbush%20Securities%20Inc.%20will%20act%20as%20co-agents%20to%20the%20company%20in%20connection%20with%20the%20transaction.%20The%20company%20intends%20to%20pay%20the%20placement%20agents%20a%20fee%20which%20equals%20to%206%25%20of%20the%20gross%20proceeds%20of%20the%20transaction.%20The%20company%20expects%20to%20pay%20placement%20agent%20fees%20of%20approximately%20%241%2C600%2C000%20to%20Leerink%20Swann%20LLC%20and%20an%20aggregate%20of%20approximately%20%24500%2C000%20to%20Ladenburg%20Thalmann%20%26%20Co.%20Inc.%2C%20Oppenheimer%20%26%20Co.%20Inc.%2C%20Roth%20Capital%20Partners%2C%20LLC%2C%20and%20Wedbush%20Securities%20Inc.%20Lia%20Der%20Marderosian%20of%20Wilmer%20Cutler%20Pickering%20Hale%20and%20Dorr%2C%20LLP%20will%20act%20as%20the%20legal%20advisor%20to%20the%20company.%20The%20securities%20will%20be%20issued%20pursuant%20to%20exemption%20provided%20under%20Regulation%20D.

OvaScience%2C%20Inc.%20%28OTCBB%3AOVSC%29%20announced%20a%20private%20placement%20of%203%2C888%2C880%20common%20shares%20at%20%249%20per%20share%20for%20gross%20proceeds%20of%20%2434%2C999%2C920%20on%20March%2012%2C%202013.%20The%20transaction%20will%20include%20participation%20from%20accredited%20investors%20including%20existing%20investors%20Blackwell%20Partners%2C%20LLC%2C%20Cycad%20Group%2C%20LLC%2C%20Hunt%20BioVentures%2C%20LP%2C%20Longwood%20Fund%2C%20LP%2C%20and%20RA%20Capital%20Healthcare%20Fund%2C%20LP%2C%20a%20fund%20managed%20by%20RA%20Capital%20Management%2C%20LLC%2C%20and%20new%20investors%20including%20Adage%20Capital%20Partners%2C%20L.P.%2C%20a%20fund%20managed%20by%20Adage%20Capital%20Management%2C%20L.P.%2C%20D3%20LifeScience%20Ltd.%2C%20Jenop%20Global%20Healthcare%20Fund%20Ltd%2C%20Franklin%20Templeton%20Investment%20Funds%20-%20Biotechnology%20Discovery%20Fund%2C%20Franklin%20Strategic%20Series%20-%20Franklin%20Biotechnology%20Discovery%20Fund%2C%20funds%20managed%20by%20Franklin%20Resources%20Inc.%2C%20Pacific%20Select%20Fund%20-%20Health%20Sciences%20Portfolio%2C%20a%20fund%20managed%20by%20Pacific%20Life%20Insurance%20Co.%2C%20Asset%20Management%20Arm%2C%20Kevin%20Beck%2C%20El%20Chichon%20Partners%2C%20LLC%2C%20BioBrit%2C%20LLC%2C%20BMV%20Direct%20LP%2C%20Jon-Erik%20Borgen%2C%20Borgen%20Equity%20III%20Holdings%2C%20LLC%2C%20Jeffrey%20David%20Capello%2C%20DAFNA%20Life%20Science%20Ltd%2C%20DAFNA%20Life%20Science%20Market%20Neutral%20Ltd%2C%20DAFNA%20Life%20Science%20Select%20Ltd%2C%20Deerfield%20Special%20Situations%20Fund%2C%20L.P.%2C%20Deerfield%20Special%20Situations%20International%20Master%20Fund%2C%20L.P.%2C%20funds%20managed%20by%20Deerfield%20Capital%2C%20L.P.%2C%20EcoR1%20Capital%20Fund%2C%20L.P.%2C%20EcoR1%20Capital%20Fund%2C%20L.P.%2C%20Hunt-BioVentures%2C%20L.P.%2C%20Janus%20Global%20Life%20Sciences%20Fund%2C%20a%20fund%20managed%20by%20INTECH%20Investment%20Management%20LLC%20and%20Janus%20Capital%20Group%2C%20Inc.%2C%20Jennison%20Global%20Healthcare%20Master%20Fund%2C%20Ltd.%2C%20a%20fund%20managed%20by%20Jennison%20Associates%20LLC%2C%20Edward%20F.%20Keely%2C%20Patrick%20Lin%2C%20Thomas%20Malley%2C%20Prudential%20Sector%20Funds%20Inc-Prudential%20Health%20Sciences%20Fund.%20The%20company%20has%20received%20%2448%2C000%2C000%20in%20funding%20till%20date.%20The%20transaction%20is%20expected%20to%20close%20by%20March%2018%2C%202013.%20Leerink%20Swann%20LLC%20will%20act%20as%20lead%20placement%20agent%20and%20Ladenburg%20Thalmann%20%26%20Co.%20Inc.%2C%20Oppenheimer%20%26%20Co.%20Inc.%2C%20Roth%20Capital%20Partners%2C%20LLC%20and%20Wedbush%20Securities%20Inc.%20will%20act%20as%20co-agents%20to%20the%20company%20in%20connection%20with%20the%20transaction.%20The%20company%20intends%20to%20pay%20the%20placement%20agents%20a%20fee%20which%20equals%20to%206%25%20of%20the%20gross%20proceeds%20of%20the%20transaction.%20The%20company%20expects%20to%20pay%20placement%20agent%20fees%20of%20approximately%20%241%2C600%2C000%20to%20Leerink%20Swann%20LLC%20and%20an%20aggregate%20of%20approximately%20%24500%2C000%20to%20Ladenburg%20Thalmann%20%26%20Co.%20Inc.%2C%20Oppenheimer%20%26%20Co.%20Inc.%2C%20Roth%20Capital%20Partners%2C%20LLC%2C%20and%20Wedbush%20Securities%20Inc.%20Lia%20Der%20Marderosian%20of%20Wilmer%20Cutler%20Pickering%20Hale%20and%20Dorr%2C%20LLP%20will%20act%20as%20the%20legal%20advisor%20to%20the%20company.%20The%20securities%20will%20be%20issued%20pursuant%20to%20exemption%20provided%20under%20Regulation%20D.

OvaScience%2C%20Inc.%20%28OTCBB%3AOVSC%29%20announced%20a%20private%20placement%20of%203%2C888%2C880%20common%20shares%20at%20%249%20per%20share%20for%20gross%20proceeds%20of%20%2434%2C999%2C920%20on%20March%2012%2C%202013.%20The%20transaction%20will%20include%20participation%20from%20accredited%20investors%20including%20existing%20investors%20Blackwell%20Partners%2C%20LLC%2C%20Cycad%20Group%2C%20LLC%2C%20Hunt%20BioVentures%2C%20LP%2C%20Longwood%20Fund%2C%20LP%2C%20and%20RA%20Capital%20Healthcare%20Fund%2C%20LP%2C%20a%20fund%20managed%20by%20RA%20Capital%20Management%2C%20LLC%2C%20and%20new%20investors%20including%20Adage%20Capital%20Partners%2C%20L.P.%2C%20a%20fund%20managed%20by%20Adage%20Capital%20Management%2C%20L.P.%2C%20D3%20LifeScience%20Ltd.%2C%20Jenop%20Global%20Healthcare%20Fund%20Ltd%2C%20Franklin%20Templeton%20Investment%20Funds%20-%20Biotechnology%20Discovery%20Fund%2C%20Franklin%20Strategic%20Series%20-%20Franklin%20Biotechnology%20Discovery%20Fund%2C%20funds%20managed%20by%20Franklin%20Resources%20Inc.%2C%20Pacific%20Select%20Fund%20-%20Health%20Sciences%20Portfolio%2C%20a%20fund%20managed%20by%20Pacific%20Life%20Insurance%20Co.%2C%20Asset%20Management%20Arm%2C%20Kevin%20Beck%2C%20El%20Chichon%20Partners%2C%20LLC%2C%20BioBrit%2C%20LLC%2C%20BMV%20Direct%20LP%2C%20Jon-Erik%20Borgen%2C%20Borgen%20Equity%20III%20Holdings%2C%20LLC%2C%20Jeffrey%20David%20Capello%2C%20DAFNA%20Life%20Science%20Ltd%2C%20DAFNA%20Life%20Science%20Market%20Neutral%20Ltd%2C%20DAFNA%20Life%20Science%20Select%20Ltd%2C%20Deerfield%20Special%20Situations%20Fund%2C%20L.P.%2C%20Deerfield%20Special%20Situations%20International%20Master%20Fund%2C%20L.P.%2C%20funds%20managed%20by%20Deerfield%20Capital%2C%20L.P.%2C%20EcoR1%20Capital%20Fund%2C%20L.P.%2C%20EcoR1%20Capital%20Fund%2C%20L.P.%2C%20Hunt-BioVentures%2C%20L.P.%2C%20Janus%20Global%20Life%20Sciences%20Fund%2C%20a%20fund%20managed%20by%20INTECH%20Investment%20Management%20LLC%20and%20Janus%20Capital%20Group%2C%20Inc.%2C%20Jennison%20Global%20Healthcare%20Master%20Fund%2C%20Ltd.%2C%20a%20fund%20managed%20by%20Jennison%20Associates%20LLC%2C%20Edward%20F.%20Keely%2C%20Patrick%20Lin%2C%20Thomas%20Malley%2C%20Prudential%20Sector%20Funds%20Inc-Prudential%20Health%20Sciences%20Fund.%20The%20company%20has%20received%20%2448%2C000%2C000%20in%20funding%20till%20date.%20The%20transaction%20is%20expected%20to%20close%20by%20March%2018%2C%202013.%20Leerink%20Swann%20LLC%20will%20act%20as%20lead%20placement%20agent%20and%20Ladenburg%20Thalmann%20%26%20Co.%20Inc.%2C%20Oppenheimer%20%26%20Co.%20Inc.%2C%20Roth%20Capital%20Partners%2C%20LLC%20and%20Wedbush%20Securities%20Inc.%20will%20act%20as%20co-agents%20to%20the%20company%20in%20connection%20with%20the%20transaction.%20The%20company%20intends%20to%20pay%20the%20placement%20agents%20a%20fee%20which%20equals%20to%206%25%20of%20the%20gross%20proceeds%20of%20the%20transaction.%20The%20company%20expects%20to%20pay%20placement%20agent%20fees%20of%20approximately%20%241%2C600%2C000%20to%20Leerink%20Swann%20LLC%20and%20an%20aggregate%20of%20approximately%20%24500%2C000%20to%20Ladenburg%20Thalmann%20%26%20Co.%20Inc.%2C%20Oppenheimer%20%26%20Co.%20Inc.%2C%20Roth%20Capital%20Partners%2C%20LLC%2C%20and%20Wedbush%20Securities%20Inc.%20Lia%20Der%20Marderosian%20of%20Wilmer%20Cutler%20Pickering%20Hale%20and%20Dorr%2C%20LLP%20will%20act%20as%20the%20legal%20advisor%20to%20the%20company.%20The%20securities%20will%20be%20issued%20pursuant%20to%20exemption%20provided%20under%20Regulation%20D.

OvaScience%2C%20Inc.%20%28OTCBB%3AOVSC%29%20announced%20a%20private%20placement%20of%203%2C888%2C880%20common%20shares%20at%20%249%20per%20share%20for%20gross%20proceeds%20of%20%2434%2C999%2C920%20on%20March%2012%2C%202013.%20The%20transaction%20will%20include%20participation%20from%20accredited%20investors%20including%20existing%20investors%20Blackwell%20Partners%2C%20LLC%2C%20Cycad%20Group%2C%20LLC%2C%20Hunt%20BioVentures%2C%20LP%2C%20Longwood%20Fund%2C%20LP%2C%20and%20RA%20Capital%20Healthcare%20Fund%2C%20LP%2C%20a%20fund%20managed%20by%20RA%20Capital%20Management%2C%20LLC%2C%20and%20new%20investors%20including%20Adage%20Capital%20Partners%2C%20L.P.%2C%20a%20fund%20managed%20by%20Adage%20Capital%20Management%2C%20L.P.%2C%20D3%20LifeScience%20Ltd.%2C%20Jenop%20Global%20Healthcare%20Fund%20Ltd%2C%20Franklin%20Templeton%20Investment%20Funds%20-%20Biotechnology%20Discovery%20Fund%2C%20Franklin%20Strategic%20Series%20-%20Franklin%20Biotechnology%20Discovery%20Fund%2C%20funds%20managed%20by%20Franklin%20Resources%20Inc.%2C%20Pacific%20Select%20Fund%20-%20Health%20Sciences%20Portfolio%2C%20a%20fund%20managed%20by%20Pacific%20Life%20Insurance%20Co.%2C%20Asset%20Management%20Arm%2C%20Kevin%20Beck%2C%20El%20Chichon%20Partners%2C%20LLC%2C%20BioBrit%2C%20LLC%2C%20BMV%20Direct%20LP%2C%20Jon-Erik%20Borgen%2C%20Borgen%20Equity%20III%20Holdings%2C%20LLC%2C%20Jeffrey%20David%20Capello%2C%20DAFNA%20Life%20Science%20Ltd%2C%20DAFNA%20Life%20Science%20Market%20Neutral%20Ltd%2C%20DAFNA%20Life%20Science%20Select%20Ltd%2C%20Deerfield%20Special%20Situations%20Fund%2C%20L.P.%2C%20Deerfield%20Special%20Situations%20International%20Master%20Fund%2C%20L.P.%2C%20funds%20managed%20by%20Deerfield%20Capital%2C%20L.P.%2C%20EcoR1%20Capital%20Fund%2C%20L.P.%2C%20EcoR1%20Capital%20Fund%2C%20L.P.%2C%20Hunt-BioVentures%2C%20L.P.%2C%20Janus%20Global%20Life%20Sciences%20Fund%2C%20a%20fund%20managed%20by%20INTECH%20Investment%20Management%20LLC%20and%20Janus%20Capital%20Group%2C%20Inc.%2C%20Jennison%20Global%20Healthcare%20Master%20Fund%2C%20Ltd.%2C%20a%20fund%20managed%20by%20Jennison%20Associates%20LLC%2C%20Edward%20F.%20Keely%2C%20Patrick%20Lin%2C%20Thomas%20Malley%2C%20Prudential%20Sector%20Funds%20Inc-Prudential%20Health%20Sciences%20Fund.%20The%20company%20has%20received%20%2448%2C000%2C000%20in%20funding%20till%20date.%20The%20transaction%20is%20expected%20to%20close%20by%20March%2018%2C%202013.%20Leerink%20Swann%20LLC%20will%20act%20as%20lead%20placement%20agent%20and%20Ladenburg%20Thalmann%20%26%20Co.%20Inc.%2C%20Oppenheimer%20%26%20Co.%20Inc.%2C%20Roth%20Capital%20Partners%2C%20LLC%20and%20Wedbush%20Securities%20Inc.%20will%20act%20as%20co-agents%20to%20the%20company%20in%20connection%20with%20the%20transaction.%20The%20company%20intends%20to%20pay%20the%20placement%20agents%20a%20fee%20which%20equals%20to%206%25%20of%20the%20gross%20proceeds%20of%20the%20transaction.%20The%20company%20expects%20to%20pay%20placement%20agent%20fees%20of%20approximately%20%241%2C600%2C000%20to%20Leerink%20Swann%20LLC%20and%20an%20aggregate%20of%20approximately%20%24500%2C000%20to%20Ladenburg%20Thalmann%20%26%20Co.%20Inc.%2C%20Oppenheimer%20%26%20Co.%20Inc.%2C%20Roth%20Capital%20Partners%2C%20LLC%2C%20and%20Wedbush%20Securities%20Inc.%20Lia%20Der%20Marderosian%20of%20Wilmer%20Cutler%20Pickering%20Hale%20and%20Dorr%2C%20LLP%20will%20act%20as%20the%20legal%20advisor%20to%20the%20company.%20The%20securities%20will%20be%20issued%20pursuant%20to%20exemption%20provided%20under%20Regulation%20D.

OvaScience%2C%20Inc.%20%28OTCBB%3AOVSC%29%20announced%20a%20private%20placement%20of%203%2C888%2C880%20common%20shares%20at%20%249%20per%20share%20for%20gross%20proceeds%20of%20%2434%2C999%2C920%20on%20March%2012%2C%202013.%20The%20transaction%20will%20include%20participation%20from%20accredited%20investors%20including%20existing%20investors%20Blackwell%20Partners%2C%20LLC%2C%20Cycad%20Group%2C%20LLC%2C%20Hunt%20BioVentures%2C%20LP%2C%20Longwood%20Fund%2C%20LP%2C%20and%20RA%20Capital%20Healthcare%20Fund%2C%20LP%2C%20a%20fund%20managed%20by%20RA%20Capital%20Management%2C%20LLC%2C%20and%20new%20investors%20including%20Adage%20Capital%20Partners%2C%20L.P.%2C%20a%20fund%20managed%20by%20Adage%20Capital%20Management%2C%20L.P.%2C%20D3%20LifeScience%20Ltd.%2C%20Jenop%20Global%20Healthcare%20Fund%20Ltd%2C%20Franklin%20Templeton%20Investment%20Funds%20-%20Biotechnology%20Discovery%20Fund%2C%20Franklin%20Strategic%20Series%20-%20Franklin%20Biotechnology%20Discovery%20Fund%2C%20funds%20managed%20by%20Franklin%20Resources%20Inc.%2C%20Pacific%20Select%20Fund%20-%20Health%20Sciences%20Portfolio%2C%20a%20fund%20managed%20by%20Pacific%20Life%20Insurance%20Co.%2C%20Asset%20Management%20Arm%2C%20Kevin%20Beck%2C%20El%20Chichon%20Partners%2C%20LLC%2C%20BioBrit%2C%20LLC%2C%20BMV%20Direct%20LP%2C%20Jon-Erik%20Borgen%2C%20Borgen%20Equity%20III%20Holdings%2C%20LLC%2C%20Jeffrey%20David%20Capello%2C%20DAFNA%20Life%20Science%20Ltd%2C%20DAFNA%20Life%20Science%20Market%20Neutral%20Ltd%2C%20DAFNA%20Life%20Science%20Select%20Ltd%2C%20Deerfield%20Special%20Situations%20Fund%2C%20L.P.%2C%20Deerfield%20Special%20Situations%20International%20Master%20Fund%2C%20L.P.%2C%20funds%20managed%20by%20Deerfield%20Capital%2C%20L.P.%2C%20EcoR1%20Capital%20Fund%2C%20L.P.%2C%20EcoR1%20Capital%20Fund%2C%20L.P.%2C%20Hunt-BioVentures%2C%20L.P.%2C%20Janus%20Global%20Life%20Sciences%20Fund%2C%20a%20fund%20managed%20by%20INTECH%20Investment%20Management%20LLC%20and%20Janus%20Capital%20Group%2C%20Inc.%2C%20Jennison%20Global%20Healthcare%20Master%20Fund%2C%20Ltd.%2C%20a%20fund%20managed%20by%20Jennison%20Associates%20LLC%2C%20Edward%20F.%20Keely%2C%20Patrick%20Lin%2C%20Thomas%20Malley%2C%20Prudential%20Sector%20Funds%20Inc-Prudential%20Health%20Sciences%20Fund.%20The%20company%20has%20received%20%2448%2C000%2C000%20in%20funding%20till%20date.%20The%20transaction%20is%20expected%20to%20close%20by%20March%2018%2C%202013.%20Leerink%20Swann%20LLC%20will%20act%20as%20lead%20placement%20agent%20and%20Ladenburg%20Thalmann%20%26%20Co.%20Inc.%2C%20Oppenheimer%20%26%20Co.%20Inc.%2C%20Roth%20Capital%20Partners%2C%20LLC%20and%20Wedbush%20Securities%20Inc.%20will%20act%20as%20co-agents%20to%20the%20company%20in%20connection%20with%20the%20transaction.%20The%20company%20intends%20to%20pay%20the%20placement%20agents%20a%20fee%20which%20equals%20to%206%25%20of%20the%20gross%20proceeds%20of%20the%20transaction.%20The%20company%20expects%20to%20pay%20placement%20agent%20fees%20of%20approximately%20%241%2C600%2C000%20to%20Leerink%20Swann%20LLC%20and%20an%20aggregate%20of%20approximately%20%24500%2C000%20to%20Ladenburg%20Thalmann%20%26%20Co.%20Inc.%2C%20Oppenheimer%20%26%20Co.%20Inc.%2C%20Roth%20Capital%20Partners%2C%20LLC%2C%20and%20Wedbush%20Securities%20Inc.%20Lia%20Der%20Marderosian%20of%20Wilmer%20Cutler%20Pickering%20Hale%20and%20Dorr%2C%20LLP%20will%20act%20as%20the%20legal%20advisor%20to%20the%20company.%20The%20securities%20will%20be%20issued%20pursuant%20to%20exemption%20provided%20under%20Regulation%20D.

OvaScience%2C%20Inc.%20%28OTCBB%3AOVSC%29%20announced%20a%20private%20placement%20of%203%2C888%2C880%20common%20shares%20at%20%249%20per%20share%20for%20gross%20proceeds%20of%20%2434%2C999%2C920%20on%20March%2012%2C%202013.%20The%20transaction%20will%20include%20participation%20from%20accredited%20investors%20including%20existing%20investors%20Blackwell%20Partners%2C%20LLC%2C%20Cycad%20Group%2C%20LLC%2C%20Hunt%20BioVentures%2C%20LP%2C%20Longwood%20Fund%2C%20LP%2C%20and%20RA%20Capital%20Healthcare%20Fund%2C%20LP%2C%20a%20fund%20managed%20by%20RA%20Capital%20Management%2C%20LLC%2C%20and%20new%20investors%20including%20Adage%20Capital%20Partners%2C%20L.P.%2C%20a%20fund%20managed%20by%20Adage%20Capital%20Management%2C%20L.P.%2C%20D3%20LifeScience%20Ltd.%2C%20Jenop%20Global%20Healthcare%20Fund%20Ltd%2C%20Franklin%20Templeton%20Investment%20Funds%20-%20Biotechnology%20Discovery%20Fund%2C%20Franklin%20Strategic%20Series%20-%20Franklin%20Biotechnology%20Discovery%20Fund%2C%20funds%20managed%20by%20Franklin%20Resources%20Inc.%2C%20Pacific%20Select%20Fund%20-%20Health%20Sciences%20Portfolio%2C%20a%20fund%20managed%20by%20Pacific%20Life%20Insurance%20Co.%2C%20Asset%20Management%20Arm%2C%20Kevin%20Beck%2C%20El%20Chichon%20Partners%2C%20LLC%2C%20BioBrit%2C%20LLC%2C%20BMV%20Direct%20LP%2C%20Jon-Erik%20Borgen%2C%20Borgen%20Equity%20III%20Holdings%2C%20LLC%2C%20Jeffrey%20David%20Capello%2C%20DAFNA%20Life%20Science%20Ltd%2C%20DAFNA%20Life%20Science%20Market%20Neutral%20Ltd%2C%20DAFNA%20Life%20Science%20Select%20Ltd%2C%20Deerfield%20Special%20Situations%20Fund%2C%20L.P.%2C%20Deerfield%20Special%20Situations%20International%20Master%20Fund%2C%20L.P.%2C%20funds%20managed%20by%20Deerfield%20Capital%2C%20L.P.%2C%20EcoR1%20Capital%20Fund%2C%20L.P.%2C%20EcoR1%20Capital%20Fund%2C%20L.P.%2C%20Hunt-BioVentures%2C%20L.P.%2C%20Janus%20Global%20Life%20Sciences%20Fund%2C%20a%20fund%20managed%20by%20INTECH%20Investment%20Management%20LLC%20and%20Janus%20Capital%20Group%2C%20Inc.%2C%20Jennison%20Global%20Healthcare%20Master%20Fund%2C%20Ltd.%2C%20a%20fund%20managed%20by%20Jennison%20Associates%20LLC%2C%20Edward%20F.%20Keely%2C%20Patrick%20Lin%2C%20Thomas%20Malley%2C%20Prudential%20Sector%20Funds%20Inc-Prudential%20Health%20Sciences%20Fund.%20The%20company%20has%20received%20%2448%2C000%2C000%20in%20funding%20till%20date.%20The%20transaction%20is%20expected%20to%20close%20by%20March%2018%2C%202013.%20Leerink%20Swann%20LLC%20will%20act%20as%20lead%20placement%20agent%20and%20Ladenburg%20Thalmann%20%26%20Co.%20Inc.%2C%20Oppenheimer%20%26%20Co.%20Inc.%2C%20Roth%20Capital%20Partners%2C%20LLC%20and%20Wedbush%20Securities%20Inc.%20will%20act%20as%20co-agents%20to%20the%20company%20in%20connection%20with%20the%20transaction.%20The%20company%20intends%20to%20pay%20the%20placement%20agents%20a%20fee%20which%20equals%20to%206%25%20of%20the%20gross%20proceeds%20of%20the%20transaction.%20The%20company%20expects%20to%20pay%20placement%20agent%20fees%20of%20approximately%20%241%2C600%2C000%20to%20Leerink%20Swann%20LLC%20and%20an%20aggregate%20of%20approximately%20%24500%2C000%20to%20Ladenburg%20Thalmann%20%26%20Co.%20Inc.%2C%20Oppenheimer%20%26%20Co.%20Inc.%2C%20Roth%20Capital%20Partners%2C%20LLC%2C%20and%20Wedbush%20Securities%20Inc.%20Lia%20Der%20Marderosian%20of%20Wilmer%20Cutler%20Pickering%20Hale%20and%20Dorr%2C%20LLP%20will%20act%20as%20the%20legal%20advisor%20to%20the%20company.%20The%20securities%20will%20be%20issued%20pursuant%20to%20exemption%20provided%20under%20Regulation%20D.

OvaScience%2C%20Inc.%20%28OTCBB%3AOVSC%29%20announced%20a%20private%20placement%20of%203%2C888%2C880%20common%20shares%20at%20%249%20per%20share%20for%20gross%20proceeds%20of%20%2434%2C999%2C920%20on%20March%2012%2C%202013.%20The%20transaction%20will%20include%20participation%20from%20accredited%20investors%20including%20existing%20investors%20Blackwell%20Partners%2C%20LLC%2C%20Cycad%20Group%2C%20LLC%2C%20Hunt%20BioVentures%2C%20LP%2C%20Longwood%20Fund%2C%20LP%2C%20and%20RA%20Capital%20Healthcare%20Fund%2C%20LP%2C%20a%20fund%20managed%20by%20RA%20Capital%20Management%2C%20LLC%2C%20and%20new%20investors%20including%20Adage%20Capital%20Partners%2C%20L.P.%2C%20a%20fund%20managed%20by%20Adage%20Capital%20Management%2C%20L.P.%2C%20D3%20LifeScience%20Ltd.%2C%20Jenop%20Global%20Healthcare%20Fund%20Ltd%2C%20Franklin%20Templeton%20Investment%20Funds%20-%20Biotechnology%20Discovery%20Fund%2C%20Franklin%20Strategic%20Series%20-%20Franklin%20Biotechnology%20Discovery%20Fund%2C%20funds%20managed%20by%20Franklin%20Resources%20Inc.%2C%20Pacific%20Select%20Fund%20-%20Health%20Sciences%20Portfolio%2C%20a%20fund%20managed%20by%20Pacific%20Life%20Insurance%20Co.%2C%20Asset%20Management%20Arm%2C%20Kevin%20Beck%2C%20El%20Chichon%20Partners%2C%20LLC%2C%20BioBrit%2C%20LLC%2C%20BMV%20Direct%20LP%2C%20Jon-Erik%20Borgen%2C%20Borgen%20Equity%20III%20Holdings%2C%20LLC%2C%20Jeffrey%20David%20Capello%2C%20DAFNA%20Life%20Science%20Ltd%2C%20DAFNA%20Life%20Science%20Market%20Neutral%20Ltd%2C%20DAFNA%20Life%20Science%20Select%20Ltd%2C%20Deerfield%20Special%20Situations%20Fund%2C%20L.P.%2C%20Deerfield%20Special%20Situations%20International%20Master%20Fund%2C%20L.P.%2C%20funds%20managed%20by%20Deerfield%20Capital%2C%20L.P.%2C%20EcoR1%20Capital%20Fund%2C%20L.P.%2C%20EcoR1%20Capital%20Fund%2C%20L.P.%2C%20Hunt-BioVentures%2C%20L.P.%2C%20Janus%20Global%20Life%20Sciences%20Fund%2C%20a%20fund%20managed%20by%20INTECH%20Investment%20Management%20LLC%20and%20Janus%20Capital%20Group%2C%20Inc.%2C%20Jennison%20Global%20Healthcare%20Master%20Fund%2C%20Ltd.%2C%20a%20fund%20managed%20by%20Jennison%20Associates%20LLC%2C%20Edward%20F.%20Keely%2C%20Patrick%20Lin%2C%20Thomas%20Malley%2C%20Prudential%20Sector%20Funds%20Inc-Prudential%20Health%20Sciences%20Fund.%20The%20company%20has%20received%20%2448%2C000%2C000%20in%20funding%20till%20date.%20The%20transaction%20is%20expected%20to%20close%20by%20March%2018%2C%202013.%20Leerink%20Swann%20LLC%20will%20act%20as%20lead%20placement%20agent%20and%20Ladenburg%20Thalmann%20%26%20Co.%20Inc.%2C%20Oppenheimer%20%26%20Co.%20Inc.%2C%20Roth%20Capital%20Partners%2C%20LLC%20and%20Wedbush%20Securities%20Inc.%20will%20act%20as%20co-agents%20to%20the%20company%20in%20connection%20with%20the%20transaction.%20The%20company%20intends%20to%20pay%20the%20placement%20agents%20a%20fee%20which%20equals%20to%206%25%20of%20the%20gross%20proceeds%20of%20the%20transaction.%20The%20company%20expects%20to%20pay%20placement%20agent%20fees%20of%20approximately%20%241%2C600%2C000%20to%20Leerink%20Swann%20LLC%20and%20an%20aggregate%20of%20approximately%20%24500%2C000%20to%20Ladenburg%20Thalmann%20%26%20Co.%20Inc.%2C%20Oppenheimer%20%26%20Co.%20Inc.%2C%20Roth%20Capital%20Partners%2C%20LLC%2C%20and%20Wedbush%20Securities%20Inc.%20Lia%20Der%20Marderosian%20of%20Wilmer%20Cutler%20Pickering%20Hale%20and%20Dorr%2C%20LLP%20will%20act%20as%20the%20legal%20advisor%20to%20the%20company.%20The%20securities%20will%20be%20issued%20pursuant%20to%20exemption%20provided%20under%20Regulation%20D.

OvaScience%2C%20Inc.%20%28OTCBB%3AOVSC%29%20announced%20a%20private%20placement%20of%203%2C888%2C880%20common%20shares%20at%20%249%20per%20share%20for%20gross%20proceeds%20of%20%2434%2C999%2C920%20on%20March%2012%2C%202013.%20The%20transaction%20will%20include%20participation%20from%20accredited%20investors%20including%20existing%20investors%20Blackwell%20Partners%2C%20LLC%2C%20Cycad%20Group%2C%20LLC%2C%20Hunt%20BioVentures%2C%20LP%2C%20Longwood%20Fund%2C%20LP%2C%20and%20RA%20Capital%20Healthcare%20Fund%2C%20LP%2C%20a%20fund%20managed%20by%20RA%20Capital%20Management%2C%20LLC%2C%20and%20new%20investors%20including%20Adage%20Capital%20Partners%2C%20L.P.%2C%20a%20fund%20managed%20by%20Adage%20Capital%20Management%2C%20L.P.%2C%20D3%20LifeScience%20Ltd.%2C%20Jenop%20Global%20Healthcare%20Fund%20Ltd%2C%20Franklin%20Templeton%20Investment%20Funds%20-%20Biotechnology%20Discovery%20Fund%2C%20Franklin%20Strategic%20Series%20-%20Franklin%20Biotechnology%20Discovery%20Fund%2C%20funds%20managed%20by%20Franklin%20Resources%20Inc.%2C%20Pacific%20Select%20Fund%20-%20Health%20Sciences%20Portfolio%2C%20a%20fund%20managed%20by%20Pacific%20Life%20Insurance%20Co.%2C%20Asset%20Management%20Arm%2C%20Kevin%20Beck%2C%20El%20Chichon%20Partners%2C%20LLC%2C%20BioBrit%2C%20LLC%2C%20BMV%20Direct%20LP%2C%20Jon-Erik%20Borgen%2C%20Borgen%20Equity%20III%20Holdings%2C%20LLC%2C%20Jeffrey%20David%20Capello%2C%20DAFNA%20Life%20Science%20Ltd%2C%20DAFNA%20Life%20Science%20Market%20Neutral%20Ltd%2C%20DAFNA%20Life%20Science%20Select%20Ltd%2C%20Deerfield%20Special%20Situations%20Fund%2C%20L.P.%2C%20Deerfield%20Special%20Situations%20International%20Master%20Fund%2C%20L.P.%2C%20funds%20managed%20by%20Deerfield%20Capital%2C%20L.P.%2C%20EcoR1%20Capital%20Fund%2C%20L.P.%2C%20EcoR1%20Capital%20Fund%2C%20L.P.%2C%20Hunt-BioVentures%2C%20L.P.%2C%20Janus%20Global%20Life%20Sciences%20Fund%2C%20a%20fund%20managed%20by%20INTECH%20Investment%20Management%20LLC%20and%20Janus%20Capital%20Group%2C%20Inc.%2C%20Jennison%20Global%20Healthcare%20Master%20Fund%2C%20Ltd.%2C%20a%20fund%20managed%20by%20Jennison%20Associates%20LLC%2C%20Edward%20F.%20Keely%2C%20Patrick%20Lin%2C%20Thomas%20Malley%2C%20Prudential%20Sector%20Funds%20Inc-Prudential%20Health%20Sciences%20Fund.%20The%20company%20has%20received%20%2448%2C000%2C000%20in%20funding%20till%20date.%20The%20transaction%20is%20expected%20to%20close%20by%20March%2018%2C%202013.%20Leerink%20Swann%20LLC%20will%20act%20as%20lead%20placement%20agent%20and%20Ladenburg%20Thalmann%20%26%20Co.%20Inc.%2C%20Oppenheimer%20%26%20Co.%20Inc.%2C%20Roth%20Capital%20Partners%2C%20LLC%20and%20Wedbush%20Securities%20Inc.%20will%20act%20as%20co-agents%20to%20the%20company%20in%20connection%20with%20the%20transaction.%20The%20company%20intends%20to%20pay%20the%20placement%20agents%20a%20fee%20which%20equals%20to%206%25%20of%20the%20gross%20proceeds%20of%20the%20transaction.%20The%20company%20expects%20to%20pay%20placement%20agent%20fees%20of%20approximately%20%241%2C600%2C000%20to%20Leerink%20Swann%20LLC%20and%20an%20aggregate%20of%20approximately%20%24500%2C000%20to%20Ladenburg%20Thalmann%20%26%20Co.%20Inc.%2C%20Oppenheimer%20%26%20Co.%20Inc.%2C%20Roth%20Capital%20Partners%2C%20LLC%2C%20and%20Wedbush%20Securities%20Inc.%20Lia%20Der%20Marderosian%20of%20Wilmer%20Cutler%20Pickering%20Hale%20and%20Dorr%2C%20LLP%20will%20act%20as%20the%20legal%20advisor%20to%20the%20company.%20The%20securities%20will%20be%20issued%20pursuant%20to%20exemption%20provided%20under%20Regulation%20D.

OvaScience%2C%20Inc.%20%28OTCBB%3AOVSC%29%20announced%20a%20private%20placement%20of%203%2C888%2C880%20common%20shares%20at%20%249%20per%20share%20for%20gross%20proceeds%20of%20%2434%2C999%2C920%20on%20March%2012%2C%202013.%20The%20transaction%20will%20include%20participation%20from%20accredited%20investors%20including%20existing%20investors%20Blackwell%20Partners%2C%20LLC%2C%20Cycad%20Group%2C%20LLC%2C%20Hunt%20BioVentures%2C%20LP%2C%20Longwood%20Fund%2C%20LP%2C%20and%20RA%20Capital%20Healthcare%20Fund%2C%20LP%2C%20a%20fund%20managed%20by%20RA%20Capital%20Management%2C%20LLC%2C%20and%20new%20investors%20including%20Adage%20Capital%20Partners%2C%20L.P.%2C%20a%20fund%20managed%20by%20Adage%20Capital%20Management%2C%20L.P.%2C%20D3%20LifeScience%20Ltd.%2C%20Jenop%20Global%20Healthcare%20Fund%20Ltd%2C%20Franklin%20Templeton%20Investment%20Funds%20-%20Biotechnology%20Discovery%20Fund%2C%20Franklin%20Strategic%20Series%20-%20Franklin%20Biotechnology%20Discovery%20Fund%2C%20funds%20managed%20by%20Franklin%20Resources%20Inc.%2C%20Pacific%20Select%20Fund%20-%20Health%20Sciences%20Portfolio%2C%20a%20fund%20managed%20by%20Pacific%20Life%20Insurance%20Co.%2C%20Asset%20Management%20Arm%2C%20Kevin%20Beck%2C%20El%20Chichon%20Partners%2C%20LLC%2C%20BioBrit%2C%20LLC%2C%20BMV%20Direct%20LP%2C%20Jon-Erik%20Borgen%2C%20Borgen%20Equity%20III%20Holdings%2C%20LLC%2C%20Jeffrey%20David%20Capello%2C%20DAFNA%20Life%20Science%20Ltd%2C%20DAFNA%20Life%20Science%20Market%20Neutral%20Ltd%2C%20DAFNA%20Life%20Science%20Select%20Ltd%2C%20Deerfield%20Special%20Situations%20Fund%2C%20L.P.%2C%20Deerfield%20Special%20Situations%20International%20Master%20Fund%2C%20L.P.%2C%20funds%20managed%20by%20Deerfield%20Capital%2C%20L.P.%2C%20EcoR1%20Capital%20Fund%2C%20L.P.%2C%20EcoR1%20Capital%20Fund%2C%20L.P.%2C%20Hunt-BioVentures%2C%20L.P.%2C%20Janus%20Global%20Life%20Sciences%20Fund%2C%20a%20fund%20managed%20by%20INTECH%20Investment%20Management%20LLC%20and%20Janus%20Capital%20Group%2C%20Inc.%2C%20Jennison%20Global%20Healthcare%20Master%20Fund%2C%20Ltd.%2C%20a%20fund%20managed%20by%20Jennison%20Associates%20LLC%2C%20Edward%20F.%20Keely%2C%20Patrick%20Lin%2C%20Thomas%20Malley%2C%20Prudential%20Sector%20Funds%20Inc-Prudential%20Health%20Sciences%20Fund.%20The%20company%20has%20received%20%2448%2C000%2C000%20in%20funding%20till%20date.%20The%20transaction%20is%20expected%20to%20close%20by%20March%2018%2C%202013.%20Leerink%20Swann%20LLC%20will%20act%20as%20lead%20placement%20agent%20and%20Ladenburg%20Thalmann%20%26%20Co.%20Inc.%2C%20Oppenheimer%20%26%20Co.%20Inc.%2C%20Roth%20Capital%20Partners%2C%20LLC%20and%20Wedbush%20Securities%20Inc.%20will%20act%20as%20co-agents%20to%20the%20company%20in%20connection%20with%20the%20transaction.%20The%20company%20intends%20to%20pay%20the%20placement%20agents%20a%20fee%20which%20equals%20to%206%25%20of%20the%20gross%20proceeds%20of%20the%20transaction.%20The%20company%20expects%20to%20pay%20placement%20agent%20fees%20of%20approximately%20%241%2C600%2C000%20to%20Leerink%20Swann%20LLC%20and%20an%20aggregate%20of%20approximately%20%24500%2C000%20to%20Ladenburg%20Thalmann%20%26%20Co.%20Inc.%2C%20Oppenheimer%20%26%20Co.%20Inc.%2C%20Roth%20Capital%20Partners%2C%20LLC%2C%20and%20Wedbush%20Securities%20Inc.%20Lia%20Der%20Marderosian%20of%20Wilmer%20Cutler%20Pickering%20Hale%20and%20Dorr%2C%20LLP%20will%20act%20as%20the%20legal%20advisor%20to%20the%20company.%20The%20securities%20will%20be%20issued%20pursuant%20to%20exemption%20provided%20under%20Regulation%20D.

OvaScience%2C%20Inc.%20%28OTCBB%3AOVSC%29%20announced%20a%20private%20placement%20of%203%2C888%2C880%20common%20shares%20at%20%249%20per%20share%20for%20gross%20proceeds%20of%20%2434%2C999%2C920%20on%20March%2012%2C%202013.%20The%20transaction%20will%20include%20participation%20from%20accredited%20investors%20including%20existing%20investors%20Blackwell%20Partners%2C%20LLC%2C%20Cycad%20Group%2C%20LLC%2C%20Hunt%20BioVentures%2C%20LP%2C%20Longwood%20Fund%2C%20LP%2C%20and%20RA%20Capital%20Healthcare%20Fund%2C%20LP%2C%20a%20fund%20managed%20by%20RA%20Capital%20Management%2C%20LLC%2C%20and%20new%20investors%20including%20Adage%20Capital%20Partners%2C%20L.P.%2C%20a%20fund%20managed%20by%20Adage%20Capital%20Management%2C%20L.P.%2C%20D3%20LifeScience%20Ltd.%2C%20Jenop%20Global%20Healthcare%20Fund%20Ltd%2C%20Franklin%20Templeton%20Investment%20Funds%20-%20Biotechnology%20Discovery%20Fund%2C%20Franklin%20Strategic%20Series%20-%20Franklin%20Biotechnology%20Discovery%20Fund%2C%20funds%20managed%20by%20Franklin%20Resources%20Inc.%2C%20Pacific%20Select%20Fund%20-%20Health%20Sciences%20Portfolio%2C%20a%20fund%20managed%20by%20Pacific%20Life%20Insurance%20Co.%2C%20Asset%20Management%20Arm%2C%20Kevin%20Beck%2C%20El%20Chichon%20Partners%2C%20LLC%2C%20BioBrit%2C%20LLC%2C%20BMV%20Direct%20LP%2C%20Jon-Erik%20Borgen%2C%20Borgen%20Equity%20III%20Holdings%2C%20LLC%2C%20Jeffrey%20David%20Capello%2C%20DAFNA%20Life%20Science%20Ltd%2C%20DAFNA%20Life%20Science%20Market%20Neutral%20Ltd%2C%20DAFNA%20Life%20Science%20Select%20Ltd%2C%20Deerfield%20Special%20Situations%20Fund%2C%20L.P.%2C%20Deerfield%20Special%20Situations%20International%20Master%20Fund%2C%20L.P.%2C%20funds%20managed%20by%20Deerfield%20Capital%2C%20L.P.%2C%20EcoR1%20Capital%20Fund%2C%20L.P.%2C%20EcoR1%20Capital%20Fund%2C%20L.P.%2C%20Hunt-BioVentures%2C%20L.P.%2C%20Janus%20Global%20Life%20Sciences%20Fund%2C%20a%20fund%20managed%20by%20INTECH%20Investment%20Management%20LLC%20and%20Janus%20Capital%20Group%2C%20Inc.%2C%20Jennison%20Global%20Healthcare%20Master%20Fund%2C%20Ltd.%2C%20a%20fund%20managed%20by%20Jennison%20Associates%20LLC%2C%20Edward%20F.%20Keely%2C%20Patrick%20Lin%2C%20Thomas%20Malley%2C%20Prudential%20Sector%20Funds%20Inc-Prudential%20Health%20Sciences%20Fund.%20The%20company%20has%20received%20%2448%2C000%2C000%20in%20funding%20till%20date.%20The%20transaction%20is%20expected%20to%20close%20by%20March%2018%2C%202013.%20Leerink%20Swann%20LLC%20will%20act%20as%20lead%20placement%20agent%20and%20Ladenburg%20Thalmann%20%26%20Co.%20Inc.%2C%20Oppenheimer%20%26%20Co.%20Inc.%2C%20Roth%20Capital%20Partners%2C%20LLC%20and%20Wedbush%20Securities%20Inc.%20will%20act%20as%20co-agents%20to%20the%20company%20in%20connection%20with%20the%20transaction.%20The%20company%20intends%20to%20pay%20the%20placement%20agents%20a%20fee%20which%20equals%20to%206%25%20of%20the%20gross%20proceeds%20of%20the%20transaction.%20The%20company%20expects%20to%20pay%20placement%20agent%20fees%20of%20approximately%20%241%2C600%2C000%20to%20Leerink%20Swann%20LLC%20and%20an%20aggregate%20of%20approximately%20%24500%2C000%20to%20Ladenburg%20Thalmann%20%26%20Co.%20Inc.%2C%20Oppenheimer%20%26%20Co.%20Inc.%2C%20Roth%20Capital%20Partners%2C%20LLC%2C%20and%20Wedbush%20Securities%20Inc.%20Lia%20Der%20Marderosian%20of%20Wilmer%20Cutler%20Pickering%20Hale%20and%20Dorr%2C%20LLP%20will%20act%20as%20the%20legal%20advisor%20to%20the%20company.%20The%20securities%20will%20be%20issued%20pursuant%20to%20exemption%20provided%20under%20Regulation%20D.

OvaScience%2C%20Inc.%20%28OTCBB%3AOVSC%29%20announced%20a%20private%20placement%20of%203%2C888%2C880%20common%20shares%20at%20%249%20per%20share%20for%20gross%20proceeds%20of%20%2434%2C999%2C920%20on%20March%2012%2C%202013.%20The%20transaction%20will%20include%20participation%20from%20accredited%20investors%20including%20existing%20investors%20Blackwell%20Partners%2C%20LLC%2C%20Cycad%20Group%2C%20LLC%2C%20Hunt%20BioVentures%2C%20LP%2C%20Longwood%20Fund%2C%20LP%2C%20and%20RA%20Capital%20Healthcare%20Fund%2C%20LP%2C%20a%20fund%20managed%20by%20RA%20Capital%20Management%2C%20LLC%2C%20and%20new%20investors%20including%20Adage%20Capital%20Partners%2C%20L.P.%2C%20a%20fund%20managed%20by%20Adage%20Capital%20Management%2C%20L.P.%2C%20D3%20LifeScience%20Ltd.%2C%20Jenop%20Global%20Healthcare%20Fund%20Ltd%2C%20Franklin%20Templeton%20Investment%20Funds%20-%20Biotechnology%20Discovery%20Fund%2C%20Franklin%20Strategic%20Series%20-%20Franklin%20Biotechnology%20Discovery%20Fund%2C%20funds%20managed%20by%20Franklin%20Resources%20Inc.%2C%20Pacific%20Select%20Fund%20-%20Health%20Sciences%20Portfolio%2C%20a%20fund%20managed%20by%20Pacific%20Life%20Insurance%20Co.%2C%20Asset%20Management%20Arm%2C%20Kevin%20Beck%2C%20El%20Chichon%20Partners%2C%20LLC%2C%20BioBrit%2C%20LLC%2C%20BMV%20Direct%20LP%2C%20Jon-Erik%20Borgen%2C%20Borgen%20Equity%20III%20Holdings%2C%20LLC%2C%20Jeffrey%20David%20Capello%2C%20DAFNA%20Life%20Science%20Ltd%2C%20DAFNA%20Life%20Science%20Market%20Neutral%20Ltd%2C%20DAFNA%20Life%20Science%20Select%20Ltd%2C%20Deerfield%20Special%20Situations%20Fund%2C%20L.P.%2C%20Deerfield%20Special%20Situations%20International%20Master%20Fund%2C%20L.P.%2C%20funds%20managed%20by%20Deerfield%20Capital%2C%20L.P.%2C%20EcoR1%20Capital%20Fund%2C%20L.P.%2C%20EcoR1%20Capital%20Fund%2C%20L.P.%2C%20Hunt-BioVentures%2C%20L.P.%2C%20Janus%20Global%20Life%20Sciences%20Fund%2C%20a%20fund%20managed%20by%20INTECH%20Investment%20Management%20LLC%20and%20Janus%20Capital%20Group%2C%20Inc.%2C%20Jennison%20Global%20Healthcare%20Master%20Fund%2C%20Ltd.%2C%20a%20fund%20managed%20by%20Jennison%20Associates%20LLC%2C%20Edward%20F.%20Keely%2C%20Patrick%20Lin%2C%20Thomas%20Malley%2C%20Prudential%20Sector%20Funds%20Inc-Prudential%20Health%20Sciences%20Fund.%20The%20company%20has%20received%20%2448%2C000%2C000%20in%20funding%20till%20date.%20The%20transaction%20is%20expected%20to%20close%20by%20March%2018%2C%202013.%20Leerink%20Swann%20LLC%20will%20act%20as%20lead%20placement%20agent%20and%20Ladenburg%20Thalmann%20%26%20Co.%20Inc.%2C%20Oppenheimer%20%26%20Co.%20Inc.%2C%20Roth%20Capital%20Partners%2C%20LLC%20and%20Wedbush%20Securities%20Inc.%20will%20act%20as%20co-agents%20to%20the%20company%20in%20connection%20with%20the%20transaction.%20The%20company%20intends%20to%20pay%20the%20placement%20agents%20a%20fee%20which%20equals%20to%206%25%20of%20the%20gross%20proceeds%20of%20the%20transaction.%20The%20company%20expects%20to%20pay%20placement%20agent%20fees%20of%20approximately%20%241%2C600%2C000%20to%20Leerink%20Swann%20LLC%20and%20an%20aggregate%20of%20approximately%20%24500%2C000%20to%20Ladenburg%20Thalmann%20%26%20Co.%20Inc.%2C%20Oppenheimer%20%26%20Co.%20Inc.%2C%20Roth%20Capital%20Partners%2C%20LLC%2C%20and%20Wedbush%20Securities%20Inc.%20Lia%20Der%20Marderosian%20of%20Wilmer%20Cutler%20Pickering%20Hale%20and%20Dorr%2C%20LLP%20will%20act%20as%20the%20legal%20advisor%20to%20the%20company.%20The%20securities%20will%20be%20issued%20pursuant%20to%20exemption%20provided%20under%20Regulation%20D.

OvaScience%2C%20Inc.%20%28OTCBB%3AOVSC%29%20announced%20a%20private%20placement%20of%203%2C888%2C880%20common%20shares%20at%20%249%20per%20share%20for%20gross%20proceeds%20of%20%2434%2C999%2C920%20on%20March%2012%2C%202013.%20The%20transaction%20will%20include%20participation%20from%20accredited%20investors%20including%20existing%20investors%20Blackwell%20Partners%2C%20LLC%2C%20Cycad%20Group%2C%20LLC%2C%20Hunt%20BioVentures%2C%20LP%2C%20Longwood%20Fund%2C%20LP%2C%20and%20RA%20Capital%20Healthcare%20Fund%2C%20LP%2C%20a%20fund%20managed%20by%20RA%20Capital%20Management%2C%20LLC%2C%20and%20new%20investors%20including%20Adage%20Capital%20Partners%2C%20L.P.%2C%20a%20fund%20managed%20by%20Adage%20Capital%20Management%2C%20L.P.%2C%20D3%20LifeScience%20Ltd.%2C%20Jenop%20Global%20Healthcare%20Fund%20Ltd%2C%20Franklin%20Templeton%20Investment%20Funds%20-%20Biotechnology%20Discovery%20Fund%2C%20Franklin%20Strategic%20Series%20-%20Franklin%20Biotechnology%20Discovery%20Fund%2C%20funds%20managed%20by%20Franklin%20Resources%20Inc.%2C%20Pacific%20Select%20Fund%20-%20Health%20Sciences%20Portfolio%2C%20a%20fund%20managed%20by%20Pacific%20Life%20Insurance%20Co.%2C%20Asset%20Management%20Arm%2C%20Kevin%20Beck%2C%20El%20Chichon%20Partners%2C%20LLC%2C%20BioBrit%2C%20LLC%2C%20BMV%20Direct%20LP%2C%20Jon-Erik%20Borgen%2C%20Borgen%20Equity%20III%20Holdings%2C%20LLC%2C%20Jeffrey%20David%20Capello%2C%20DAFNA%20Life%20Science%20Ltd%2C%20DAFNA%20Life%20Science%20Market%20Neutral%20Ltd%2C%20DAFNA%20Life%20Science%20Select%20Ltd%2C%20Deerfield%20Special%20Situations%20Fund%2C%20L.P.%2C%20Deerfield%20Special%20Situations%20International%20Master%20Fund%2C%20L.P.%2C%20funds%20managed%20by%20Deerfield%20Capital%2C%20L.P.%2C%20EcoR1%20Capital%20Fund%2C%20L.P.%2C%20EcoR1%20Capital%20Fund%2C%20L.P.%2C%20Hunt-BioVentures%2C%20L.P.%2C%20Janus%20Global%20Life%20Sciences%20Fund%2C%20a%20fund%20managed%20by%20INTECH%20Investment%20Management%20LLC%20and%20Janus%20Capital%20Group%2C%20Inc.%2C%20Jennison%20Global%20Healthcare%20Master%20Fund%2C%20Ltd.%2C%20a%20fund%20managed%20by%20Jennison%20Associates%20LLC%2C%20Edward%20F.%20Keely%2C%20Patrick%20Lin%2C%20Thomas%20Malley%2C%20Prudential%20Sector%20Funds%20Inc-Prudential%20Health%20Sciences%20Fund.%20The%20company%20has%20received%20%2448%2C000%2C000%20in%20funding%20till%20date.%20The%20transaction%20is%20expected%20to%20close%20by%20March%2018%2C%202013.%20Leerink%20Swann%20LLC%20will%20act%20as%20lead%20placement%20agent%20and%20Ladenburg%20Thalmann%20%26%20Co.%20Inc.%2C%20Oppenheimer%20%26%20Co.%20Inc.%2C%20Roth%20Capital%20Partners%2C%20LLC%20and%20Wedbush%20Securities%20Inc.%20will%20act%20as%20co-agents%20to%20the%20company%20in%20connection%20with%20the%20transaction.%20The%20company%20intends%20to%20pay%20the%20placement%20agents%20a%20fee%20which%20equals%20to%206%25%20of%20the%20gross%20proceeds%20of%20the%20transaction.%20The%20company%20expects%20to%20pay%20placement%20agent%20fees%20of%20approximately%20%241%2C600%2C000%20to%20Leerink%20Swann%20LLC%20and%20an%20aggregate%20of%20approximately%20%24500%2C000%20to%20Ladenburg%20Thalmann%20%26%20Co.%20Inc.%2C%20Oppenheimer%20%26%20Co.%20Inc.%2C%20Roth%20Capital%20Partners%2C%20LLC%2C%20and%20Wedbush%20Securities%20Inc.%20Lia%20Der%20Marderosian%20of%20Wilmer%20Cutler%20Pickering%20Hale%20and%20Dorr%2C%20LLP%20will%20act%20as%20the%20legal%20advisor%20to%20the%20company.%20The%20securities%20will%20be%20issued%20pursuant%20to%20exemption%20provided%20under%20Regulation%20D.

OvaScience%2C%20Inc.%20%28OTCBB%3AOVSC%29%20announced%20a%20private%20placement%20of%203%2C888%2C880%20common%20shares%20at%20%249%20per%20share%20for%20gross%20proceeds%20of%20%2434%2C999%2C920%20on%20March%2012%2C%202013.%20The%20transaction%20will%20include%20participation%20from%20accredited%20investors%20including%20existing%20investors%20Blackwell%20Partners%2C%20LLC%2C%20Cycad%20Group%2C%20LLC%2C%20Hunt%20BioVentures%2C%20LP%2C%20Longwood%20Fund%2C%20LP%2C%20and%20RA%20Capital%20Healthcare%20Fund%2C%20LP%2C%20a%20fund%20managed%20by%20RA%20Capital%20Management%2C%20LLC%2C%20and%20new%20investors%20including%20Adage%20Capital%20Partners%2C%20L.P.%2C%20a%20fund%20managed%20by%20Adage%20Capital%20Management%2C%20L.P.%2C%20D3%20LifeScience%20Ltd.%2C%20Jenop%20Global%20Healthcare%20Fund%20Ltd%2C%20Franklin%20Templeton%20Investment%20Funds%20-%20Biotechnology%20Discovery%20Fund%2C%20Franklin%20Strategic%20Series%20-%20Franklin%20Biotechnology%20Discovery%20Fund%2C%20funds%20managed%20by%20Franklin%20Resources%20Inc.%2C%20Pacific%20Select%20Fund%20-%20Health%20Sciences%20Portfolio%2C%20a%20fund%20managed%20by%20Pacific%20Life%20Insurance%20Co.%2C%20Asset%20Management%20Arm%2C%20Kevin%20Beck%2C%20El%20Chichon%20Partners%2C%20LLC%2C%20BioBrit%2C%20LLC%2C%20BMV%20Direct%20LP%2C%20Jon-Erik%20Borgen%2C%20Borgen%20Equity%20III%20Holdings%2C%20LLC%2C%20Jeffrey%20David%20Capello%2C%20DAFNA%20Life%20Science%20Ltd%2C%20DAFNA%20Life%20Science%20Market%20Neutral%20Ltd%2C%20DAFNA%20Life%20Science%20Select%20Ltd%2C%20Deerfield%20Special%20Situations%20Fund%2C%20L.P.%2C%20Deerfield%20Special%20Situations%20International%20Master%20Fund%2C%20L.P.%2C%20funds%20managed%20by%20Deerfield%20Capital%2C%20L.P.%2C%20EcoR1%20Capital%20Fund%2C%20L.P.%2C%20EcoR1%20Capital%20Fund%2C%20L.P.%2C%20Hunt-BioVentures%2C%20L.P.%2C%20Janus%20Global%20Life%20Sciences%20Fund%2C%20a%20fund%20managed%20by%20INTECH%20Investment%20Management%20LLC%20and%20Janus%20Capital%20Group%2C%20Inc.%2C%20Jennison%20Global%20Healthcare%20Master%20Fund%2C%20Ltd.%2C%20a%20fund%20managed%20by%20Jennison%20Associates%20LLC%2C%20Edward%20F.%20Keely%2C%20Patrick%20Lin%2C%20Thomas%20Malley%2C%20Prudential%20Sector%20Funds%20Inc-Prudential%20Health%20Sciences%20Fund.%20The%20company%20has%20received%20%2448%2C000%2C000%20in%20funding%20till%20date.%20The%20transaction%20is%20expected%20to%20close%20by%20March%2018%2C%202013.%20Leerink%20Swann%20LLC%20will%20act%20as%20lead%20placement%20agent%20and%20Ladenburg%20Thalmann%20%26%20Co.%20Inc.%2C%20Oppenheimer%20%26%20Co.%20Inc.%2C%20Roth%20Capital%20Partners%2C%20LLC%20and%20Wedbush%20Securities%20Inc.%20will%20act%20as%20co-agents%20to%20the%20company%20in%20connection%20with%20the%20transaction.%20The%20company%20intends%20to%20pay%20the%20placement%20agents%20a%20fee%20which%20equals%20to%206%25%20of%20the%20gross%20proceeds%20of%20the%20transaction.%20The%20company%20expects%20to%20pay%20placement%20agent%20fees%20of%20approximately%20%241%2C600%2C000%20to%20Leerink%20Swann%20LLC%20and%20an%20aggregate%20of%20approximately%20%24500%2C000%20to%20Ladenburg%20Thalmann%20%26%20Co.%20Inc.%2C%20Oppenheimer%20%26%20Co.%20Inc.%2C%20Roth%20Capital%20Partners%2C%20LLC%2C%20and%20Wedbush%20Securities%20Inc.%20Lia%20Der%20Marderosian%20of%20Wilmer%20Cutler%20Pickering%20Hale%20and%20Dorr%2C%20LLP%20will%20act%20as%20the%20legal%20advisor%20to%20the%20company.%20The%20securities%20will%20be%20issued%20pursuant%20to%20exemption%20provided%20under%20Regulation%20D.

Janus%20Capital%20Group%2C%20Inc.%20%28NYSE%3AJNS%29%20agreed%20to%20acquire%20an%20additional%2021.76%25%20stake%20in%20Perkins%20Investment%20Management%20LLC%20from%20founders%20of%20Perkins%20Investment%20Management%20on%20February%201%2C%202013.%20The%20non-controlling%20owners%20of%20Perkins%20i.e.%20founders%20of%20Perkins%20Investment%20exercised%20their%20right%20to%20put%2098%25%20of%20their%20interests%20to%20Janus%20Capital.%20Under%20the%20terms%20of%20the%20put%2C%20the%20non-controlling%20ownership%20interests%20of%20the%20founders%20will%20be%20redeemed%20at%20fair%20value%20as%20determined%20six%20months%20from%20the%20date%20of%20the%20put%20exercise.